$GRYP
Gryphon Digital Mining, Inc. Stock $gryp

$gryp Overview Financials Valuation SEC Filings Company Website

2022 Q1 Form 10-K Financial Statement

#000121390022016675 Filed on March 31, 2022

Income Statement

Concept	2022 Q1	2021 Q4	2021
Revenue	$6.951M	$2.400M	$20.68M
YoY Change	73.16%	-41.61%	64.52%
Cost Of Revenue	$2.204M	$2.780M	$8.119M
YoY Change	51.54%	98.54%	30.75%
Gross Profit	$4.747M	$3.849M	$12.57M
YoY Change	85.45%	42.03%	97.46%
Gross Profit Margin	68.3%	160.38%	60.75%
Selling, General & Admin	$5.807M	$5.659M	$19.53M
YoY Change	61.79%	48.93%	2.18%
% of Gross Profit	122.32%	147.04%	155.43%
Research & Development	$2.105M	$1.754M	$6.272M
YoY Change	47.84%	24.41%	95.61%
% of Gross Profit	44.35%	45.57%	49.91%
Depreciation & Amortization	$1.993M	$2.130M	$127.7K
YoY Change	89.33%	153.54%	-90.29%
% of Gross Profit	41.99%	55.33%	1.02%
Operating Expenses	$25.38M	$9.543M	$45.92M
YoY Change	318.47%	58.0%	94.29%
Operating Profit	-$20.64M	-$5.694M	-$33.36M
YoY Change	488.61%	71.0%	93.12%
Interest Expense	-$740.00	$406.3K	-$1.531M
YoY Change	-100.1%	-121.05%	-1077.48%
% of Operating Profit
Other Income/Expense, Net	-$1.416M	$186.2K	-$228.1K
YoY Change	-51.87%	-410.3%	-107.91%
Pretax Income	-$22.05M	-$19.49M	-$33.58M
YoY Change	242.02%	59.71%	133.42%
Income Tax	-$99.44K	-$2.273M	-$2.262M
% Of Pretax Income
Net Earnings	-$21.95M	$400.0K	-$31.33M
YoY Change	239.95%	-103.27%	130.83%
Net Earnings / Revenue	-315.83%	16.67%	-151.46%
Basic Earnings Per Share			-$24.44
Diluted Earnings Per Share	-$694.6K	-$580.9K	-$1.222M
COMMON SHARES
Basic Shares Outstanding	32.05M shares	30.74M shares	1.282M shares
Diluted Shares Outstanding	1.580M shares

Balance Sheet

Concept	2022 Q1	2021 Q4	2021
SHORT-TERM ASSETS
Cash & Short-Term Investments	$9.688M	$13.93M	$13.93M
YoY Change	-37.22%	-21.89%	-21.89%
Cash & Equivalents	$9.688M	$13.93M
Short-Term Investments
Other Short-Term Assets	$2.453M	$2.385M	$2.385M
YoY Change	20.23%	-19.42%	1.49%
Inventory
Prepaid Expenses	$2.492M	$2.384M
Receivables	$2.579M	$1.404M	$1.404M
Other Receivables	$547.7K	$507.0K	$507.0K
Total Short-Term Assets	$15.27M	$18.23M	$18.23M
YoY Change	-23.32%	-19.17%	-19.16%
LONG-TERM ASSETS
Property, Plant & Equipment	$159.2K	$153.2K	$153.2K
YoY Change	-86.03%	-87.17%	-87.13%
Goodwill	$29.96M	$46.94M
YoY Change	-28.44%	12.1%
Intangibles		$21.61M
YoY Change		192.47%
Long-Term Investments	$226.1K	$226.1K	$226.1K
YoY Change	-1.7%	-3.24%	-1.7%
Other Assets	$9.700K	$9.700K	$9.700K
YoY Change
Total Long-Term Assets	$59.08M	$76.25M	$76.25M
YoY Change	8.56%	39.62%	39.61%
TOTAL ASSETS
Total Short-Term Assets	$15.27M	$18.23M	$18.23M
Total Long-Term Assets	$59.08M	$76.25M	$76.25M
Total Assets	$74.35M	$94.48M	$94.48M
YoY Change	0.02%	22.44%	22.44%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.066M	$1.943M	$1.943M
YoY Change	518.34%	278.39%	281.07%
Accrued Expenses	$3.208M	$3.439M	$3.439M
YoY Change	25.31%		28.8%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$13.20M	$13.20M	$13.20M
YoY Change	50.34%	12.75%	12.72%
Total Short-Term Liabilities	$30.38M	$29.17M	$29.17M
YoY Change	126.11%	81.73%	85.33%
LONG-TERM LIABILITIES
Long-Term Debt	$2.137M	$4.105M	$4.105M
YoY Change	89.12%	5.39%	5.26%
Other Long-Term Liabilities	$486.2K	$582.7K	$582.7K
YoY Change
Total Long-Term Liabilities	$2.137M	$4.105M	$4.688M
YoY Change	89.12%	5.39%	20.2%
TOTAL LIABILITIES
Total Short-Term Liabilities	$30.38M	$29.17M	$29.17M
Total Long-Term Liabilities	$2.137M	$4.105M	$4.688M
Total Liabilities	$33.57M	$34.53M	$34.53M
YoY Change	130.49%	73.13%	75.83%
SHAREHOLDERS EQUITY
Retained Earnings	-$110.5M	-$88.51M
YoY Change	73.58%	54.79%
Common Stock	$148.8M	$146.0M
YoY Change	34.14%	55.21%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$40.78M	$59.95M	$59.95M
YoY Change
Total Liabilities & Shareholders Equity	$74.35M	$94.48M	$94.48M
YoY Change	0.02%	22.44%	22.44%

Cashflow Statement

Concept	2022 Q1	2021 Q4	2021
OPERATING ACTIVITIES
Net Income	-$21.95M	$400.0K	-$31.33M
YoY Change	239.95%	-103.27%	130.83%
Depreciation, Depletion And Amortization	$1.993M	$2.130M	$127.7K
YoY Change	89.33%	153.54%	-90.29%
Cash From Operating Activities	-$3.585M	-$3.090M	-$8.168M
YoY Change	160.98%	-31.78%	-43.07%
INVESTING ACTIVITIES
Capital Expenditures	-$647.0K	-$2.101M	-$5.466M
YoY Change	-7.57%	72.17%	193.9%
Acquisitions			$5.019M
YoY Change			5556.66%
Other Investing Activities		-$5.019M	-$5.019M
YoY Change		2289.8%	-4.95%
Cash From Investing Activities	-$647.0K	-$7.119M	-$10.49M
YoY Change	-8.18%	394.38%	191.41%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change
Debt Paid & Issued, Net			$4.571M
YoY Change
Cash From Financing Activities	-$5.615K	14.51M	$14.74M
YoY Change	-98.32%	52.1%	-27.17%
NET CHANGE
Cash From Operating Activities	-$3.585M	-3.090M	-$8.168M
Cash From Investing Activities	-$647.0K	-7.119M	-$10.49M
Cash From Financing Activities	-$5.615K	14.51M	$14.74M
Net Change In Cash	-$4.247M	4.301M	-$3.917M
YoY Change	75.92%	20.47%	-271.15%
FREE CASH FLOW
Cash From Operating Activities	-$3.585M	-$3.090M	-$8.168M
Capital Expenditures	-$647.0K	-$2.101M	-$5.466M
Free Cash Flow	-$2.938M	-$989.9K	-$2.701M
YoY Change	336.08%	-70.09%	-78.37%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	kern	Gain Loss On Loan Forgiveness GainLossOnLoanForgiveness		USD
	kern	Adjustments Due To The Adoption Of Asc606 AdjustmentsDueToTheAdoptionOfASC606	185826	USD
	kern	Warrants Issued In Period Number Of Shares WarrantsIssuedInPeriodNumberOfShares		shares
	kern	Warrants Issued In Period Weighted Average Grant Date Fair Value WarrantsIssuedInPeriodWeightedAverageGrantDateFairValue
	kern	Warrants Exercised In Period Number Of Shares WarrantsExercisedInPeriodNumberOfShares		shares
	kern	Warrants Exercised In Period Weighted Average Grant Date Fair Value WarrantsExercisedInPeriodWeightedAverageGrantDateFairValue
	kern	Weighted Average Remaining Life Term Exercised WeightedAverageRemainingLifeTermExercised
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		USD
CY2021	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2021	dei	Document Transition Report DocumentTransitionReport	false
CY2021	dei	Document Annual Report DocumentAnnualReport	true
CY2021	dei	Entity Address State Or Province EntityAddressStateOrProvince	CO
CY2021	dei	Entity Registrant Name EntityRegistrantName	Akerna Corp.
CY2021	dei	Entity Central Index Key EntityCentralIndexKey	0001755953
CY2021	dei	Amendment Flag AmendmentFlag	false
CY2021	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2021	dei	Entity Shell Company EntityShellCompany	false
CY2021	dei	Entity Small Business EntitySmallBusiness	true
CY2021	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2021	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2021	dei	Document Type DocumentType	10-K
CY2021	dei	Document Period End Date DocumentPeriodEndDate	2021-12-31
CY2021	dei	Entity File Number EntityFileNumber	001-39096
CY2021	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	83-2242651
CY2021	dei	Entity Address Address Line1 EntityAddressAddressLine1	1550 Larimer Street
CY2021	dei	Entity Address City Or Town EntityAddressCityOrTown	Denver
CY2021	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	80202
CY2021	dei	City Area Code CityAreaCode	(888)
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	153151	USD
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	6300000	USD
CY2020Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent		USD
CY2021Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	3543819	USD
CY2021	dei	Local Phone Number LocalPhoneNumber	932-6537
CY2021	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value per share
CY2021	dei	Trading Symbol TradingSymbol	KERN
CY2021	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2021	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2021	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021Q2	dei	Entity Public Float EntityPublicFloat	94600000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1193433	USD
CY2021Q4	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	226101	USD
CY2020Q4	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	233664	USD
CY2020Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	843900	USD
CY2021Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	13200000	USD
CY2020Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	11707363	USD
CY2021Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	63178	USD
CY2020Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	311376	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	29170517	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	16051215	USD
CY2021Q4	us-gaap	Capitalized Computer Software Net CapitalizedComputerSoftwareNet	7311676	USD
CY2020Q4	us-gaap	Capitalized Computer Software Net CapitalizedComputerSoftwareNet	3925739	USD
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	21609794	USD
CY2020Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	7388795	USD
CY2021Q4	us-gaap	Goodwill Goodwill	46942681	USD
CY2020Q4	us-gaap	Goodwill Goodwill	41874527	USD
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	9700	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent		USD
CY2021Q4	us-gaap	Assets Assets	94483167	USD
CY2020Q4	us-gaap	Assets Assets	77169072	USD
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	6063520	USD
CY2020Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	3188576	USD
CY2021Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	582676	USD
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	4105000	USD
CY2020Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	3895237	USD
CY2022Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	32054463	shares
CY2021	dei	Auditor Firm AuditorFirmId	688
CY2021	dei	Auditor Name AuditorName	Marcum LLP
CY2021	dei	Auditor Location AuditorLocation	Los Angeles, CA
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	17840640	USD
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	508261	USD
CY2020Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	500000	USD
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1403774	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1753547	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2383764	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2458727	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	18230064	USD
CY2021Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	675291	USD
CY2020Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent		USD
CY2021Q4	us-gaap	Liabilities Liabilities	34533484	USD
CY2020Q4	us-gaap	Liabilities Liabilities	19946452	USD
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	1	shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	1	shares
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10422207	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4435067	USD
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	1	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	1	shares
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2021Q4	kern	Exchangable Preferred Stock ExchangablePreferredStock	2366038	USD
CY2020Q4	kern	Exchangable Preferred Stock ExchangablePreferredStock	20405219	USD
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	31001884	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	31001884	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	19901248	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	19901248	shares
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	3100	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	1990	USD
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	146027258	USD
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	94086433	USD
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	61523	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-91497	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-88508236	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-57179525	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	59949683	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	57222620	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	94483167	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	77169072	USD
CY2021	us-gaap	Revenues Revenues	20684974	USD
	us-gaap	Revenues Revenues	7824784	USD
CY2020	us-gaap	Revenues Revenues	12573276	USD
CY2021	us-gaap	Cost Of Revenue CostOfRevenue	8119487	USD
	us-gaap	Cost Of Revenue CostOfRevenue	3141041	USD
CY2020	us-gaap	Cost Of Revenue CostOfRevenue	6209724	USD
CY2021	us-gaap	Gross Profit GrossProfit	12565487	USD
	us-gaap	Gross Profit GrossProfit	4683743	USD
CY2020	us-gaap	Gross Profit GrossProfit	6363552	USD
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6271966	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3166088	USD
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3206310	USD
CY2021	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	9108173	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	3928028	USD
CY2020	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	7792480	USD
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11320715	USD
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	5735150	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2007237	USD
CY2020	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1315898	USD
CY2021	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	14383310	USD
	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	6887000	USD
CY2020	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse		USD
CY2021	us-gaap	Operating Expenses OperatingExpenses	45920806	USD
	us-gaap	Operating Expenses OperatingExpenses	20423420	USD
CY2020	us-gaap	Operating Expenses OperatingExpenses	23635403	USD
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-33355319	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-15739677	USD
CY2020	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-849759	USD
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-31175691	USD
CY2021	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	25641950	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	16056030	shares
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	11860212	shares
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-228053	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-466778	USD
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2884458	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-33583372	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-16206455	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-14387393	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-2262225	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	200	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	30985	USD
CY2021	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.22
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.01
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.14
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-17271851	USD
CY2021	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-1531497	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-193084	USD
CY2020	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	156678	USD
CY2021	kern	Change In Fair Value Of Convertible Debt ChangeInFairValueOfConvertibleDebt	1365904	USD
	kern	Change In Fair Value Of Convertible Debt ChangeInFairValueOfConvertibleDebt	961273	USD
CY2020	kern	Change In Fair Value Of Convertible Debt ChangeInFairValueOfConvertibleDebt	-766000	USD
CY2021	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	248198	USD
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	746852	USD
CY2020	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	1962034	USD
CY2021	kern	Gain On Ppp Loan Forgiveness GainOnPPPLoanForgiveness	2234730	USD
	kern	Gain On Ppp Loan Forgiveness GainOnPPPLoanForgiveness		USD
CY2020	kern	Gain On Ppp Loan Forgiveness GainOnPPPLoanForgiveness		USD
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	186420	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-59273	USD
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-254	USD
CY2021	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-7564	USD
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-12641	USD
CY2020	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-3692	USD
CY2021	us-gaap	Profit Loss ProfitLoss	-31328711	USD
	us-gaap	Profit Loss ProfitLoss	-16219296	USD
CY2020	us-gaap	Profit Loss ProfitLoss	-14422070	USD
CY2021	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest		USD
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-8815	USD
CY2020	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-849759	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-31328711	USD
	us-gaap	Net Income Loss NetIncomeLoss	-16210481	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-13572311	USD
CY2021	us-gaap	Profit Loss ProfitLoss	-31328711	USD
	us-gaap	Profit Loss ProfitLoss	-16219296	USD
CY2020	us-gaap	Profit Loss ProfitLoss	-14422070	USD
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	53020	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-21497	USD
CY2020	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax		USD
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	100000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-133000	USD
CY2020	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	63000	USD
CY2021	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-31175691	USD
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-16373793	USD
CY2020	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-14359070	USD
CY2021	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest		USD
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-8815	USD
	us-gaap	Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings	185825	USD
	kern	Stockholders Equity Beginning Balance StockholdersEquityBeginningBalance	35702003	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	11032380	USD
CY2021	kern	Stock Issued During Period Value Settlement Of Liabilities StockIssuedDuringPeriodValueSettlementOfLiabilities	430025	USD
CY2021	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross		USD
CY2021	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures		USD
	kern	Special Voting Preferred Stock Issued In Business Combination SpecialVotingPreferredStockIssuedInBusinessCombination	25203490	USD
	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits		USD
	kern	Noncontrolling Interests In Acquired Subsidiary NoncontrollingInterestsInAcquiredSubsidiary		USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1298540	USD
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	360000	USD
	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross		USD
	kern	Stock Issued During Period Change In Fair Value Of Debt StockIssuedDuringPeriodChangeInFairValueOfDebt	-133000	USD
	us-gaap	Temporary Equity Foreign Currency Translation Adjustments TemporaryEquityForeignCurrencyTranslationAdjustments	-21497	USD
	us-gaap	Profit Loss ProfitLoss	-16219296	USD
CY2021	us-gaap	Temporary Equity Foreign Currency Translation Adjustments TemporaryEquityForeignCurrencyTranslationAdjustments	53020	USD
CY2021	kern	Stock Issued During Period Change In Fair Value Of Debt StockIssuedDuringPeriodChangeInFairValueOfDebt	100000	USD
CY2021	us-gaap	Profit Loss ProfitLoss	-31328711	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	59949683	USD
CY2021	us-gaap	Profit Loss ProfitLoss	-31328711	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-16364978	USD
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-13509311	USD
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	18717734	USD
CY2020	kern	Stock Issued During Period Value Warrant Exercise StockIssuedDuringPeriodValueWarrantExercise	4247065	USD
CY2020	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	20081466	USD
CY2020	kern	Non Controlling Interest In Acquired Subsidiary NonControllingInterestInAcquiredSubsidiary	5554011	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1253234	USD
CY2020	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures		USD
CY2020	kern	Increase Decrease In Fair Value Of Convertible Notes IncreaseDecreaseInFairValueOfConvertibleNotes	63000	USD
CY2020	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	21738	USD
CY2020	us-gaap	Profit Loss ProfitLoss	-14422070	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	35516178	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	57222620	USD
CY2021	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits		USD
CY2021	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	11610586	USD
CY2021	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	520395	USD
CY2021	kern	Shares Issued In Connection With Viridian Acquisition SharesIssuedInConnectionWithViridianAcquisition	6188000	USD
CY2021	us-gaap	Stock Issued During Period Value Purchase Of Assets StockIssuedDuringPeriodValuePurchaseOfAssets	300000	USD
CY2021	kern	Sharesissuedinconnectionwith365 Cannabis Acquisition Sharesissuedinconnectionwith365CannabisAcquisition	11996061	USD
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2070358	USD
CY2021	kern	Cash Received In Connection With Exercise Of Warrants CashReceivedInConnectionWithExerciseOfWarrants	1828119	USD
	us-gaap	Profit Loss ProfitLoss	-16219296	USD
CY2020	us-gaap	Profit Loss ProfitLoss	-14422070	USD
CY2021	us-gaap	Loss On Sale Of Investments LossOnSaleOfInvestments	7564	USD
	us-gaap	Loss On Sale Of Investments LossOnSaleOfInvestments	12643	USD
CY2020	us-gaap	Loss On Sale Of Investments LossOnSaleOfInvestments	3692	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	72832	USD
CY2020	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	1094507	USD
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	2070359	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1197589	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	1166130	USD
CY2021	us-gaap	Assets Disposed Of By Method Other Than Sale In Period Of Disposition Gain Loss On Disposition1 AssetsDisposedOfByMethodOtherThanSaleInPeriodOfDispositionGainLossOnDisposition1	-1045179	USD
	us-gaap	Assets Disposed Of By Method Other Than Sale In Period Of Disposition Gain Loss On Disposition1 AssetsDisposedOfByMethodOtherThanSaleInPeriodOfDispositionGainLossOnDisposition1		USD
CY2020	us-gaap	Assets Disposed Of By Method Other Than Sale In Period Of Disposition Gain Loss On Disposition1 AssetsDisposedOfByMethodOtherThanSaleInPeriodOfDispositionGainLossOnDisposition1		USD
CY2021	kern	Gain Loss On Loan Forgiveness GainLossOnLoanForgiveness	-2234730	USD
CY2021	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	5018592	USD
CY2020	kern	Gain Loss On Loan Forgiveness GainLossOnLoanForgiveness		USD
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	5735150	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2007237	USD
CY2020	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1315898	USD
CY2021	us-gaap	Amortization Of Acquisition Costs AmortizationOfAcquisitionCosts	492683	USD
	us-gaap	Amortization Of Acquisition Costs AmortizationOfAcquisitionCosts	228766	USD
CY2020	us-gaap	Amortization Of Acquisition Costs AmortizationOfAcquisitionCosts		USD
CY2021	us-gaap	Other Noncash Expense OtherNoncashExpense	1009331	USD
	us-gaap	Other Noncash Expense OtherNoncashExpense	32727	USD
CY2020	us-gaap	Other Noncash Expense OtherNoncashExpense		USD
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	3312	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax		USD
CY2020	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax		USD
CY2021	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	14383310	USD
	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	6887000	USD
CY2020	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf		USD
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	186177	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		USD
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		USD
CY2021	us-gaap	Gain Loss On Sale Of Other Assets GainLossOnSaleOfOtherAssets		USD
	us-gaap	Gain Loss On Sale Of Other Assets GainLossOnSaleOfOtherAssets	-84835	USD
CY2020	us-gaap	Gain Loss On Sale Of Other Assets GainLossOnSaleOfOtherAssets		USD
CY2021	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts		USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts		USD
CY2020	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1177390	USD
CY2021	kern	Change In Fair Value Of Convertible Debt ChangeInFairValueOfConvertibleDebt	1365904	USD
	kern	Change In Fair Value Of Convertible Debt ChangeInFairValueOfConvertibleDebt	961273	USD
CY2020	kern	Change In Fair Value Of Convertible Debt ChangeInFairValueOfConvertibleDebt	-766000	USD
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	746852	USD
CY2020	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	1962034	USD
CY2021	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Asset1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1		USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Asset1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1	993000	USD
CY2020	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Asset1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1	998000	USD
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-849785	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1008775	USD
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1621262	USD
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	8988	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	689729	USD
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	592807	USD
CY2021	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets		USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-41925	USD
CY2020	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	58925	USD
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1610470	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-2498375	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1602751	USD
CY2021	us-gaap	Increase Decrease In Other Deferred Liability IncreaseDecreaseInOtherDeferredLiability	-2274295	USD
	us-gaap	Increase Decrease In Other Deferred Liability IncreaseDecreaseInOtherDeferredLiability		USD
CY2020	us-gaap	Increase Decrease In Other Deferred Liability IncreaseDecreaseInOtherDeferredLiability		USD
CY2021	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-1010118	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-94088	USD
CY2020	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-286922	USD
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8167904	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8705738	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-14347652	USD
CY2021	us-gaap	Payments To Develop Software PaymentsToDevelopSoftware	5427230	USD
	us-gaap	Payments To Develop Software PaymentsToDevelopSoftware	1847710	USD
CY2020	us-gaap	Payments To Develop Software PaymentsToDevelopSoftware	3102728	USD
CY2021	us-gaap	Payments To Acquire Furniture And Fixtures PaymentsToAcquireFurnitureAndFixtures	39263	USD
	us-gaap	Payments To Acquire Furniture And Fixtures PaymentsToAcquireFurnitureAndFixtures	12203	USD
CY2020	us-gaap	Payments To Acquire Furniture And Fixtures PaymentsToAcquireFurnitureAndFixtures	156636	USD
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	5279134	USD
CY2020	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	88720	USD
CY2021	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments		USD
	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments		USD
CY2020	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	250000	USD
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-10485085	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-7139047	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3598084	USD
CY2021	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	520395	USD
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation		USD
CY2020	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation		USD
CY2021	us-gaap	Proceeds From Contributed Capital ProceedsFromContributedCapital	1828119	USD
	us-gaap	Proceeds From Contributed Capital ProceedsFromContributedCapital		USD
CY2020	us-gaap	Proceeds From Contributed Capital ProceedsFromContributedCapital		USD
CY2021	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	18000000	USD
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt		USD
CY2020	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	17164600	USD
CY2021	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments		USD
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments		USD
CY2020	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments		USD
CY2021	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	4571472	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	1500000	USD
CY2020	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt		USD
CY2021	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts		USD
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts		USD
CY2020	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	1177390	USD
CY2021	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		USD
CY2020	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	4247065	USD
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	12000000	USD
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		USD
CY2021	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts		USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	967620	USD
CY2020	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts		USD
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	14736252	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	9532380	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	20234275	USD
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	18623	USD
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-2783	USD
CY2020	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents		USD
CY2021	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-3898114	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-6315188	USD
CY2020	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	2288539	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	18340640	USD
CY2020Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	24655828	USD
CY2019Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	22367289	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	14442526	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	18340640	USD
CY2020Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	24655828	USD
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	-10570	USD
CY2020	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		USD
CY2021	us-gaap	Interest Paid Net InterestPaidNet	507941	USD
	us-gaap	Interest Paid Net InterestPaidNet	150000	USD
CY2020	us-gaap	Interest Paid Net InterestPaidNet		USD
CY2021	kern	Adjustments Due To The Adoption Of Asc606 AdjustmentsDueToTheAdoptionOfASC606		USD
CY2021	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	18038944	USD
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	4798271	USD
CY2020	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1		USD
CY2021	kern	Adjustmentto Trellis Purchase Price Allocation AdjustmenttoTrellisPurchasePriceAllocation		USD
	kern	Adjustmentto Trellis Purchase Price Allocation AdjustmenttoTrellisPurchasePriceAllocation	14300	USD
CY2020	kern	Adjustmentto Trellis Purchase Price Allocation AdjustmenttoTrellisPurchasePriceAllocation		USD
CY2021	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	430015	USD
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1		USD
CY2020	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1		USD
CY2020Q2	kern	Acquisition Of Goodwill AcquisitionOfGoodwill	20254309	USD
CY2021Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accounts Payable BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable	1174961	USD
CY2020Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accounts Payable BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable	805114	USD
CY2020Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accounts Payable BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable	1441062	USD
CY2021Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Deferred Tax Liabilities BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities	2949586	USD
CY2020Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Deferred Revenue BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue	549311	USD
CY2020	kern	Adjustments Due To The Adoption Of Asc606 AdjustmentsDueToTheAdoptionOfASC606		USD
CY2021	kern	Vesting Of Restricted Stock Units VestingOfRestrictedStockUnits	42	USD
	kern	Vesting Of Restricted Stock Units VestingOfRestrictedStockUnits	15	USD
CY2020	kern	Vesting Of Restricted Stock Units VestingOfRestrictedStockUnits		USD
CY2021	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	11610586	USD
	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	327273	USD
CY2020	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1		USD
CY2021	kern	Stock Based Compensation Capitalized As Software Development StockBasedCompensationCapitalizedAsSoftwareDevelopment	36915	USD
	kern	Stock Based Compensation Capitalized As Software Development StockBasedCompensationCapitalizedAsSoftwareDevelopment	100951	USD
CY2020	kern	Stock Based Compensation Capitalized As Software Development StockBasedCompensationCapitalizedAsSoftwareDevelopment	87104	USD
CY2021	kern	Acquisition Of Noncontrolling Interest AcquisitionOfNoncontrollingInterest		USD
	kern	Acquisition Of Noncontrolling Interest AcquisitionOfNoncontrollingInterest	4695437	USD
CY2020	kern	Acquisition Of Noncontrolling Interest AcquisitionOfNoncontrollingInterest		USD
CY2021	kern	Capitalized Software Included In Accrued Expenses CapitalizedSoftwareIncludedInAccruedExpenses	554127	USD
	kern	Capitalized Software Included In Accrued Expenses CapitalizedSoftwareIncludedInAccruedExpenses	189198	USD
CY2020	kern	Capitalized Software Included In Accrued Expenses CapitalizedSoftwareIncludedInAccruedExpenses		USD
CY2021	kern	Special Voting Preferred Stock Issued In Business Combination SpecialVotingPreferredStockIssuedInBusinessCombination		USD
	kern	Special Voting Preferred Stock Issued In Business Combination SpecialVotingPreferredStockIssuedInBusinessCombination	25203490	USD
CY2020	kern	Special Voting Preferred Stock Issued In Business Combination SpecialVotingPreferredStockIssuedInBusinessCombination		USD
CY2021	kern	Shares Issued In Connection With An Asset Purchase SharesIssuedInConnectionWithAnAssetPurchase	8	USD
	kern	Shares Issued In Connection With An Asset Purchase SharesIssuedInConnectionWithAnAssetPurchase		USD
CY2020	kern	Shares Issued In Connection With An Asset Purchase SharesIssuedInConnectionWithAnAssetPurchase		USD
CY2021Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents	527346	USD
CY2020Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents	445269	USD
CY2020Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents		USD
CY2021Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Receivables BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables	1041912	USD
CY2020Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Receivables BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables	917205	USD
CY2020Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Receivables BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables	77505	USD
CY2021Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Prepaid Expense And Other Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets	408973	USD
CY2020Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Prepaid Expense And Other Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets	596233	USD
CY2020Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Prepaid Expense And Other Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets	27860	USD
CY2021Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Property Plant And Equipment BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment	93365	USD
CY2020Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Property Plant And Equipment BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment	1326996	USD
CY2020Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Property Plant And Equipment BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment	2410	USD
CY2021Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangible Assets Other Than Goodwill BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill	16933000	USD
CY2020Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangible Assets Other Than Goodwill BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill	3795000	USD
CY2020Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangible Assets Other Than Goodwill BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill	8010000	USD
CY2021Q4	kern	Acquisition Of Goodwill AcquisitionOfGoodwill	19451464	USD
CY2020Q4	kern	Acquisition Of Goodwill AcquisitionOfGoodwill	25805615	USD
CY2020Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Deferred Tax Liabilities BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities		USD
CY2020Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Deferred Tax Liabilities BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities		USD
CY2021Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Deferred Revenue BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue	4301514	USD
CY2020Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Deferred Revenue BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue	31220	USD
CY2021Q4	kern	Contingent Consideration ContingentConsideration	6300000	USD
CY2020Q4	kern	Contingent Consideration ContingentConsideration	604000	USD
CY2020Q2	kern	Contingent Consideration ContingentConsideration	1387000	USD
CY2021	us-gaap	Nature Of Operations NatureOfOperations	<p style="margin: 0pt; text-align: justify;"><span style="font-weight: bold;"><span>Note 1</span><span> </span></span><span><span>-</span></span><span style="font-weight: bold; font-family: 'times new roman', times; font-size: 10pt;"><span>Description of Bu<span>sines</span>s, Liquidity, and Capital</span> <span>Resources</span></span></p> <p style="margin: 0pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span></p> <p style="margin: 0pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">Description of Business</span></p> <p style="margin: 0pt; text-align: justify;"><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span></p> <p style="color: #000000; font: 10pt / 1.2 'Times New Roman', Times, serif; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt; text-align: justify; text-indent: 32pt;"><span style="font-family: 'times new roman', times; line-height: inherit;">Akerna Corp., herein referred to as we, us, our or Akerna, through our wholly-owned subsidiaries MJ Freeway, LLC, or MJF, Trellis Solutions, Inc., or Trellis, <span style="font-size: 10pt; font-family: 'Times New Roman', serif; color: #000000; position: relative; top: 0.5pt; line-height: inherit;">Ample Organics, Inc, or Ample, </span>solo sciences, inc., or Solo, Viridian Sciences Inc., or Viridian, and The NAV People, Inc. d.b.a. 365 Cannabis, or 365 Cannabis, provides enterprise software solutions that enable regulatory compliance and inventory management. Our proprietary, broad and growing suite of solutions are adaptable for industries in which interfacing with government regulatory agencies for compliance purposes is required, or where the tracking of organic materials from seed or plant to end products is desired. We develop products intended to assist states in monitoring licensed businesses’ compliance with state regulations and to help state-licensed businesses operate in compliance with such law. We provide <span style="color: #000000; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: justify; text-indent: 48px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; line-height: inherit;">o<span style="font-size: 10pt; line-height: inherit;">ur commercial software platform, MJ Platform®, Trellis®, Ample, Viridian and 365 Cannabis to state-licensed businesses, and </span></span><span style="font-size: 10pt; line-height: inherit;">our regulatory software platform, Leaf Data Systems®, to state government regulatory agencies.</span> <span style="font-size: 10pt; color: #000000; position: relative; top: 0.5pt; line-height: inherit;">Through Solo, we provide an innovative, next-generation solution for state and national governments to securely track product and waste throughout the supply chain with soloTAG</span><sup><span style="font-size: 6.5pt; color: #000000; position: relative; top: 0.5pt; line-height: inherit;">™</span></sup><span style="font-size: 10pt; color: #000000; position: relative; top: 0.5pt; line-height: inherit;">. </span>The integration of MJ Platform® and soloCODE<sup>™ </sup>results in technology for consumers and brands that brings a consumer-facing mark designed to highlight the authenticity and signify transparency. Our Viridian and 365 Cannabis offerings are considered enterprise offerings and all other solutions are considered non-enterprise offerings that meet the needs of our small and medium business customers. </span></p> <p style="color: #000000; font: 10pt / 1.2 'Times New Roman', Times, serif; letter-spacing: normal; orphans: 2; text-indent: 32pt; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt; text-align: justify;"> </p> <p style="color: #000000; font: 10pt / 1.2 'Times New Roman', Times, serif; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt; text-align: justify; text-indent: 32pt;"><span style="font-family: 'times new roman', times; line-height: inherit;">We consult with clients on a wide range of areas to help them successfully maintain compliance with state laws and regulations. We provide project-focused consulting services to clients who are initiating or expanding their cannabis business operations or are interested in data consulting engagements with respect to the legal cannabis industry. Our advisory engagements include service offerings focused on compliance requirement assessments, readiness and best practices, compliance monitoring systems, application processes, inspection readiness, and business plan and compliance reviews. We typically provide our consulting services to clients in emerging markets that are seeking consultation on newly introduced licensing regimes and assistance with the regulatory compliant build-out of operations. </span><br/></p> <p style="color: #000000; font: 10pt 'Times New Roman', Times, serif; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt; text-align: justify; text-indent: 32pt;"><br/></p> <p style="margin: 0pt; line-height: 1.2;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; line-height: inherit;">Going Concern and Management's Liquidity Plans</span></p> <p style="margin: 0pt; text-align: justify; line-height: 1.1;"><span style="font-family: 'Times New Roman'; font-size: 10pt; line-height: inherit;"> </span></p> <p style="margin: 0pt; color: #000000; font-family: 'times new roman', times; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: #ffffff; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 32pt; line-height: 1.2;"><span style="font-family: 'times new roman', times; font-size: 10pt;">In accordance with the Financial Accounting Standards Board’s (“FASB”) standard on going concern, Accounting Standard Update, or ASU No. 2014-15, The Company assesses going concern uncertainty in its consolidated financial statements to determine if it has sufficient cash, cash equivalents and working capital on hand, including marketable equity securities, and any available borrowings on loans, to operate for a period of at least one year from the date the consolidated financial statements are issued, which is referred to as the “look-forward period” as defined by ASU No. 2014-15. As part of this assessment, based on conditions that are known and reasonably knowable to The Company, it will consider various scenarios, forecasts, projections, estimates and will make certain key assumptions, including the timing and nature of projected cash expenditures or programs, and its ability to delay or curtail expenditures or programs, if necessary, among other factors. Based on this assessment, as necessary or applicable, The Company makes certain assumptions around implementing curtailments or delays in the nature and timing of programs and expenditures to the extent The Company deems probable those implementations can be achieved and it has the proper authority to execute them within the look-forward period in accordance with ASU No. 2014-15.</span></p> <p style="margin: 0pt; color: #000000; font-family: 'times new roman', times; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: #ffffff; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 32pt; line-height: 1.2;"><br/></p> <p style="margin: 0pt; color: #000000; font-family: 'times new roman', times; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: #ffffff; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 32pt; line-height: 1.2;"><span style="font-family: 'times new roman', times; font-size: 10pt;"><span style="color: #000000; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: justify; text-indent: 42.6667px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-family: 'times new roman', times; line-height: inherit;"><span style="color: #000000; font-family: 'times new roman', times; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: justify; text-indent: 42.6667px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;">The accompanying consolidated financial statements have been prepared on the basis that we will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business.<span> However, since</span></span> our inception we have incurred recurring operating losses, used cash from operations, and relied on capital raising transactions to continue ongoing operations. </span><span style="color: #000000; font-family: 'time new roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: justify; text-indent: 42.6667px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; line-height: inherit;">During the year ended<span> </span>December 31, 2021, six months ended December 31, 2020, and year ended June 30, 2020, we incurred a loss from operations of $33.4<span> </span>million,<span> </span><span style="color: #000000; font-family: 'time new roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: justify; text-indent: 42.6667px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;">$15.7</span><span style="color: #000000; font-family: 'time new roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: justify; text-indent: 42.6667px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;"> million</span>, and<span> </span><span style="color: #000000; font-family: 'time new roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: justify; text-indent: 42.6667px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;">$17.3</span><span style="color: #000000; font-family: 'time new roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: justify; text-indent: 42.6667px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;"> million, respectively, and<span><span> </span>used cash in operations of</span></span><span> $8.2<span> million, $</span>8.7 million, and $14.3 million, res</span>pectively. At December 31, 2021, the Company had a working capital<span> </span>defici<span>t of $10.9</span><span><span> </span>million with $</span><span>13.9</span><span> million in</span><span> </span>cash available to fund future operations. <span style="color: #000000; font-family: 'times new roman', times; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: justify; text-indent: 42.6667px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;">These factors raise substantial doubt, as defined by generally accepted accounting principles in the United States of America ("GAAP"), about the ability of the company to continue to operate as a going concern for the<span> </span>twelve<span> </span>months following the issuance of these consolidated financial statements. These consolidated financial statements do not include any adjustments related to the recoverability and classification of assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. </span></span><br/></span></p> <p style="margin: 0pt; color: #000000; font-family: 'times new roman', times; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: #ffffff; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 32pt; line-height: 1.2;"><br/></p> <p style="margin: 0pt; color: #000000; font-family: 'times new roman', times; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: #ffffff; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 32pt; line-height: 1.2;"><span style="font-family: 'times new roman', times; font-size: 10pt;">On July 23, 2021, we entered into an Equity Distribution Agreement with Oppenheimer & Co.<span> </span>Inc. and A.G.P./Alliance Global Partners ("ATM Program"). Pursuant to the terms of the ATM Program, we may offer and sell from time to time, up to $25<span> </span>million of shares of our common stock. As of December 31, 2021, we have raised gross proceeds of $1.9<span> </span>million through the issuance of<span> </span>556,388<span> </span>shares through the ATM program. While no assurance can be provided that we will be able to raise further capital under the program, we intend to use the net proceeds from the sale of our shares of common stock, if any, for general corporate purposes, including working capital, marketing, product development, capital expenditures and merger and acquisition activities. </span></p> <p style="margin: 0px; color: #000000; font-family: 'times new roman', times; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: #ffffff; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"><br/></p> <p style="margin: 0pt; color: #000000; font-family: 'times new roman', times; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: #ffffff; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 32pt; line-height: 1.2;"><span style="font-family: 'times new roman', times; font-size: 10pt;">On October 5, 2021, we entered into a securities purchase agreement with the<span> </span>two<span> </span>institutional investors that held the Company's convertible notes issued in June of<span> </span>2020<span> </span>(the "2020<span> </span>Notes") to sell senior secured notes in a private placement (the "Senior Convertible Notes"). The Senior Convertible Notes have an aggregate principal amount of $20 million, an aggregate original issue discount of<span> </span>10%, and rank senior to all our other outstanding and future indebtedness. Approximately $3.3<span> </span>million of the proceeds from the Senior Convertible Notes were used to payoff the<span> </span>2020<span> </span>Notes, which were then to be cancelled. The net proceeds from the issuance of the Senior Convertible Notes was approximately $14.6<span> </span>million, following the original issue discount and deductions for expenses and<span> </span>paydown<span> </span>of the<span> </span>2020<span> </span>Notes. These net proceeds will be used to support<span> </span>Akerna's<span> </span>ongoing growth initiatives and continued investment in current and future technology infrastructure. The Senior Convertible Notes are convertible into shares of common stock of<span> </span>Akerna<span> </span>at a conversion price of $4.05 per share.<span> </span><span style="border-right: none; border-left: none;">The Senior Convertible Notes mature on October 5, 2024 and are to be repaid in monthly installments beginning on January 1, 2022. The Senior Convertible Notes can be repaid in common shares or cash.</span></span></p> <p style="margin: 0pt; color: #000000; font-family: 'times new roman', times; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: #ffffff; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 32pt; line-height: 1.2;"><br/></p> <p style="text-align: justify; text-indent: 32pt; margin: 0pt; line-height: 1.2;"><span style="font-family: 'Times New Roman', 'serif'; text-indent: 42.6667px; float: none; display: inline !important;">Management’s plan for the Company to continue as a going concern includes raising additional capital from our ATM program, subject to certain effects on the Senior Convertible Notes should we utilize the program, including resetting the conversion price of the Senior Convertible Notes should we raise more than $<span>5 million</span> under the ATM program, settling our contingent consideration and Senior Convertible Notes in common stock rather than cash as it comes due, and implementing certain cost cutting strategies throughout the organization, while continuing to seek to grow our customer base and realize synergies as we continue to integrate our recent acquisitions. If the Company is unable to raise sufficient additional funds through the ATM Program, it will have to develop and implement a plan to extend payables, reduce expenditures, or scale back our business plan until sufficient additional capital is raised through other equity or debt offerings to support further operations. Such offerings may include the issuance of shares of common stock, warrants to purchase common stock, preferred stock, convertible debt or other instruments that may dilute our current stockholders.</span><span style="font-family: 'Times New Roman', 'serif'; text-indent: 42.6667px;"> </span><br/></p> <p style="text-align: justify; text-indent: 32pt; margin: 0pt; line-height: 1.2;"><br/></p> <p style="text-align: justify; text-indent: 32pt; margin: 0pt; line-height: 1.2; font-family: 'times new roman', times; font-size: 10pt;">The ability of the Company to continue as a going concern is dependent upon its ability to successfully accomplish the plans described in the preceding paragraph and eventually secure other sources of financing and attain profitable operations. We will require additional financing in the second quarter of 2022 to meet our ongoing operational working capital requirements and continue to meet the financial covenants of the Senior Convertible Notes. As noted above, we plan to meet those requirements in part through the use of our ATM Facility, but there are no guarantees that the ATM Facility will permit us to raise sufficient cash to meet our ongoing requirements. These factors raise substantial doubt about the Company’s ability to continue as a going concern for one year from the issuance of the consolidated financial statements. If we are unable to raise sufficient capital we may have to reduce operations which could significantly affect our results of operations. If we fail to meet the financial covenants of the Senior Convertible Notes and cannot obtain a waiver from such provisions or otherwise come to an agreement with the holders of our debt, such holders may declare a default on the debt which could subject our assets to seizure and sale, negatively impacting our business. The accompanying consolidated financial statements do not include any adjustments relating to the recoverability and classification of assets and liabilities that might be necessary if the Company is unable to continue as a going concern.</p>
CY2021Q4	kern	Working Capital Deficit WorkingCapitalDeficit	10900000	USD
CY2021Q4	us-gaap	Cash Cash	13900000	USD
CY2021Q3	kern	Common Stock Value Issued CommonStockValueIssued	25000000	USD
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1900000	USD
CY2021	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	556388	shares
CY2021Q3	us-gaap	Secured Debt SecuredDebt	20000000	USD
CY2021Q4	kern	Default Interest Rate DefaultInterestRate	0.10	pure
CY2021Q4	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	3300000	USD
CY2021Q4	kern	Conversion Pricepershare ConversionPricepershare	4.05
CY2021Q4	us-gaap	Debt Instrument Maturity Date Description DebtInstrumentMaturityDateDescription	The Senior Convertible Notes mature on October 5, 2024 and are to be repaid in monthly installments beginning on January 1, 2022. The Senior Convertible Notes can be repaid in common shares or cash.
CY2021	us-gaap	Use Of Estimates UseOfEstimates	<p style="margin: 0pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; font-style: italic;">Use of Estimates</span></p> <p style="margin: 0pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span></p> <p style="margin: 0pt; text-align: justify; text-indent: 32pt; line-height: 1.2;"><span style="color: #000000; font-family: 'times new roman', times; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: justify; text-indent: 48px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; line-height: inherit;">The preparation of our consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts included in the consolidated financial statements and accompanying notes thereto. Our most significant estimates and assumptions are related to the valuation of acquisition-related assets and liabilities, capitalization of internal costs associated with software development, fair value measurements, impairment assessments, loss contingencies, valuation allowance associated with deferred tax assets, stock based compensation expenses, and useful lives of long-lived intangible assets. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances. Accordingly, actual results could differ from those estimates. </span></p>
CY2021	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p style="margin: 0pt; color: #000000; font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; font-style: italic;">Reclassifications</span></p> <p style="margin: 0pt; color: #000000; font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; padding-left: 30px;"><br/></p> <p style="margin: 0pt; color: #000000; font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: justify; text-indent: 32pt; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; padding-left: 0px; line-height: 1.2;"><span style="color: #000000; font-family: 'times new roman', times; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;">Certain prior year amounts have been reclassified to conform to the current year presentation.</span></p>
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	300000	USD
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	200000	USD
CY2020Q4	us-gaap	Accounts Receivable Gross AccountsReceivableGross	153500	USD
CY2020Q2	us-gaap	Accounts Receivable Gross AccountsReceivableGross	208422	USD
CY2021	kern	Bad Debt Expenses BadDebtExpenses	556890	USD
	kern	Bad Debt Expenses BadDebtExpenses	72832	USD
CY2021	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	393306	USD
	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	127754	USD
CY2021Q4	us-gaap	Accounts Receivable Gross AccountsReceivableGross	317084	USD
CY2020Q4	us-gaap	Accounts Receivable Gross AccountsReceivableGross	153500	USD
CY2021	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="border-left: none; border-right: none;"> <p style="margin: 0pt; text-align: justify;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; font-style: italic;">Concentrations </span><span style="font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">of Credit Risk</span><br/></p> </div> <div style="font-family: 'times new roman', times; border-right: none; border-left: none;"> <div style="border-left: none; border-right: none;"> <div style="border-left: none; border-right: none;"> <p style="margin: 0pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span></p> <p style="margin: 0pt; text-align: justify; text-indent: 32pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt;">We grant credit in the normal course of business to customers in the United States. We periodically perform credit analysis and monitor the financial condition of our customers to reduce credit risk.</span></p> <p style="margin: 0pt; text-align: justify; text-indent: 32pt;"><br/></p> <p style="margin: 0pt; text-align: justify; text-indent: 32pt; line-height: 1.2; font-family: 'times new roman', times; font-size: 10pt;"><span><span style="line-height: inherit;">During the year ended December 31, 2021, the six months ended December 31, 2020 and the year ended June 30, 2</span><span><span>020, </span><span><span>one</span></span><span> government client accounted for 11%, </span></span>14<span><span style="line-height: inherit;"><span>% and 25% of total revenues, respectively.</span></span><span style="line-height: inherit;"><span> As of December 31, 2020, </span></span><span style="line-height: inherit;">two government clients accounted f<span>or a total of 36% </span></span><span style="line-height: inherit;">of net accounts receivable. </span></span></span></p> <p style="margin: 0pt; text-align: justify; text-indent: 32pt; line-height: 1.2;"><span><span><span style="line-height: inherit;"><br/></span></span></span></p> </div> <div> </div> <p style="margin: 0pt; text-align: justify; text-indent: 32pt;"><br/></p> </div> </div>
CY2021	kern	Leaseholdimprovementsusefullife Leaseholdimprovementsusefullife	Lesser of remaining lease term or useful life
CY2020	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	2700000	USD
CY2021	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	14.4	USD
CY2020	kern	Impairment Of Intangible Assets ImpairmentOfIntangibleAssets	4200000	USD
CY2021	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	28847	USD
CY2021	kern	Product Development Stage Costs ProductDevelopmentStageCosts	5900000	USD
CY2020	kern	Product Development Stage Costs ProductDevelopmentStageCosts	2100000	USD
CY2020	kern	Product Development Stage Costs ProductDevelopmentStageCosts	3100000	USD
CY2021Q4	us-gaap	Noncurrent Assets NoncurrentAssets	37585	USD
CY2020Q4	us-gaap	Noncurrent Assets NoncurrentAssets	15068	USD
CY2021	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-31423	USD
CY2021Q4	kern	Deferred Revenue Revenue Recognized DeferredRevenueRevenueRecognized	11100000	USD
CY2020Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	0.2	USD
CY2021	kern	Deferral Of Contract Costs DeferralOfContractCosts	200000	USD
CY2021	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	20685000	USD
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	7825	USD
CY2020	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	12573	USD
CY2021	kern	Adjustedforadoption Adjustedforadoption	20685000	USD
CY2020	kern	Adjustedforadoption Adjustedforadoption	7825000	USD
CY2020	kern	Adjustedforadoption Adjustedforadoption	12573	USD
CY2021Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	16.6	USD
CY2021	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	1.1	USD
CY2020	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	1.8	USD
CY2020Q4	us-gaap	Deferred Revenue DeferredRevenue	844000	USD
CY2021	us-gaap	Deferred Revenue Additions DeferredRevenueAdditions	12657000	USD
CY2021	us-gaap	Deferred Revenue Revenue Recognized1 DeferredRevenueRevenueRecognized1	9375000	USD
CY2021Q4	us-gaap	Deferred Revenue DeferredRevenue	4126000	USD
CY2021Q4	kern	Revenuerecognized Revenuerecognized	20700000	USD
CY2020Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	0.7	USD
CY2020Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	228	USD
CY2021	us-gaap	Additions To Contract Holders Funds AdditionsToContractHoldersFunds	512000	USD
CY2021	kern	Amortized Costs AmortizedCosts	479000	USD
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	261000	USD
CY2021Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1	shares
CY2021Q2	us-gaap	Business Combination Consideration Transferred Including Equity Interest In Acquiree Held Prior To Combination1 BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1	6188	USD
CY2021Q4	us-gaap	Revenues Revenues	2400000	USD
CY2021Q4	us-gaap	Net Income Loss NetIncomeLoss	400000	USD
CY2020	us-gaap	Business Combination Consideration Transferred1 BusinessCombinationConsiderationTransferred1	0	USD
CY2021Q4	kern	Assetsand Liability Acquired AssetsandLiabilityAcquired	14300	USD
CY2020Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1950000	shares
CY2020Q1	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	9
CY2020Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	800000	shares
CY2020	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	14026	USD
CY2020	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	27523	USD
CY2020	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-17650	USD
CY2020	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-20250	USD
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Liquidation Preference PreferredStockLiquidationPreference	1
CY2020Q3	kern	Exchangeable Shares ExchangeableShares	627225	shares
CY2020Q3	us-gaap	Shares Issued SharesIssued	4798271	shares
CY2020Q4	us-gaap	Shares Issued SharesIssued	309286	shares
CY2021Q4	kern	Prepaid Expenses Software And Technology PrepaidExpensesSoftwareAndTechnology	687740	USD
CY2020Q4	kern	Prepaid Expenses Software And Technology PrepaidExpensesSoftwareAndTechnology	480651	USD
CY2021Q4	kern	Prepaid Professional Fees PrepaidProfessionalFees	546126	USD
CY2020Q4	kern	Prepaid Professional Fees PrepaidProfessionalFees	826195	USD
CY2021Q4	us-gaap	Prepaid Insurance PrepaidInsurance	264097	USD
CY2020Q4	us-gaap	Prepaid Insurance PrepaidInsurance	243222	USD
CY2021Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	260899	USD
CY2020Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	227718	USD
CY2021Q4	us-gaap	Unbilled Contracts Receivable UnbilledContractsReceivable	506984	USD
CY2020Q4	us-gaap	Unbilled Contracts Receivable UnbilledContractsReceivable	612446	USD
CY2021Q4	us-gaap	Other Assets OtherAssets	117918	USD
CY2020Q4	us-gaap	Other Assets OtherAssets	68495	USD
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	2383764	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1943457	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	513610	USD
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	319590	USD
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	233667	USD
CY2021Q4	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	360361	USD
CY2020Q4	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	216367	USD
CY2021Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	1123467	USD
CY2020Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	311379	USD
CY2021Q4	kern	Accrued Contractors AccruedContractors	1288730	USD
CY2020Q4	kern	Accrued Contractors AccruedContractors	538618	USD
CY2021Q4	us-gaap	Settlement Liabilities Current SettlementLiabilitiesCurrent	681045	USD
CY2020Q4	us-gaap	Settlement Liabilities Current SettlementLiabilitiesCurrent	831232	USD
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	346870	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	543703	USD
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	6063520	USD
CY2020Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	3188576	USD
CY2019Q4	us-gaap	Goodwill Goodwill	20254309	USD
CY2020	us-gaap	Goodwill Other Increase Decrease GoodwillOtherIncreaseDecrease	14300	USD
CY2020	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	25806518	USD
CY2020	kern	Goodwillimpairmentrelatedto Ample GoodwillimpairmentrelatedtoAmple	4172000	USD
CY2020Q4	us-gaap	Goodwill Goodwill	41874527	USD
CY2021	us-gaap	Goodwill Other Increase Decrease GoodwillOtherIncreaseDecrease	5408884	USD
CY2021	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	14042580	USD
CY2021	kern	Goodwillimpairmentrelatedto Ample GoodwillimpairmentrelatedtoAmple	-14383310	USD
CY2021Q4	us-gaap	Goodwill Goodwill	46942681	USD
CY2020	kern	Impairment Adjustment ImpairmentAdjustment	4200000	USD
CY2021	kern	Impairment Expenses ImpairmentExpenses	14400000	USD
CY2021Q4	kern	Weightingtothemarketapproach Weightingtothemarketapproach	0.25	pure
CY2021Q4	kern	Weightedtotheincomeapproach Weightedtotheincomeapproach	0.75	pure
CY2021	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P1Y9M
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	25600000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	3990207	USD
CY2021Q4	kern	Finite Lived Intangiable Assets Impairment FiniteLivedIntangiableAssetsImpairment		USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	21609793	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	11805000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1701205	USD
CY2020Q4	kern	Finite Lived Intangiable Assets Impairment FiniteLivedIntangiableAssetsImpairment	2715000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	7388795	USD
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	5600000	USD
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1.8	USD
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1300000	USD
CY2021	us-gaap	Capitalized Computer Software Amortization1 CapitalizedComputerSoftwareAmortization1	300000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	249106	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1306856	USD
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	95955	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	113423	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	153151	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1193433	USD
CY2021	us-gaap	Depreciation Depreciation	127731	USD
	us-gaap	Depreciation Depreciation	240742	USD
CY2020	us-gaap	Depreciation Depreciation	27951	USD
CY2021Q4	kern	Wrote Of Fixed Assets WroteOfFixedAssets	1200000	USD
	us-gaap	Proceeds From Sale Of Furniture And Fixtures ProceedsFromSaleOfFurnitureAndFixtures	25561	USD
CY2020Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	191389	USD
	kern	Accumulated Depreciation AccumulatedDepreciation	106555	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	59273	USD
CY2021Q4	kern	Equity Loss Of Investee EquityLossOfInvestee	12641	USD
CY2021	kern	Revenue Recognized RevenueRecognized	25900	USD
	kern	Revenue Recognized RevenueRecognized	0	USD
CY2020	kern	Revenue Recognized RevenueRecognized	0	USD
CY2021Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	17305000	USD
CY2021Q4	kern	Current Maturities CurrentMaturities	13200000	USD
CY2021Q4	us-gaap	Other Long Term Debt OtherLongTermDebt	4105000	USD
CY2020Q2	us-gaap	Debt Instrument Annual Principal Payment DebtInstrumentAnnualPrincipalPayment	17	USD
CY2020Q2	kern	Debt Instrument Interest Rate Original Issue Discount Percentage DebtInstrumentInterestRateOriginalIssueDiscountPercentage	0.12	pure
CY2020Q2	us-gaap	Other Ownership Interests Value OtherOwnershipInterestsValue	880	USD
CY2020Q2	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	1000	USD
CY2020Q2	us-gaap	Debt Conversion Original Debt Interest Rate Of Debt DebtConversionOriginalDebtInterestRateOfDebt	0.15	pure
CY2021	kern	Debt Instrument Conversion Floor Price DebtInstrumentConversionFloorPrice	1.92
CY2021Q4	kern	Fair Value Issuance Amount FairValueIssuanceAmount	15	USD
CY2020	us-gaap	Debt Instrument Increase Decrease For Period Net DebtInstrumentIncreaseDecreaseForPeriodNet	800000	USD
CY2020	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	100000	USD
CY2020	us-gaap	Interest Expense Other InterestExpenseOther	700000	USD
CY2020Q4	us-gaap	Debt Instrument Annual Principal Payment DebtInstrumentAnnualPrincipalPayment	1800000	USD
CY2020Q4	kern	Settled In Cash SettledInCash	1500000	USD
CY2020Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	300000	USD
CY2020Q4	kern	Convertible Notes Increased ConvertibleNotesIncreased	1000000	USD
	us-gaap	Concentration Risk Credit Risk Financial Instrument Maximum Exposure ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure	100000	USD
	us-gaap	Interest Expense Other InterestExpenseOther	900000	USD
CY2020Q4	kern	Convertible Notes ConvertibleNotes	13400000	USD
CY2021Q4	us-gaap	Debt Instrument Annual Principal Payment DebtInstrumentAnnualPrincipalPayment	15200000	USD
CY2021Q4	kern	Settled In Cash SettledInCash	5100000	USD
CY2021Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	10100000	USD
CY2021Q4	kern	Convertible Notes Increased ConvertibleNotesIncreased	2000000	USD
CY2021	us-gaap	Concentration Risk Credit Risk Financial Instrument Maximum Exposure ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure	20000.00	USD
CY2021	us-gaap	Interest Expense Other InterestExpenseOther	2000000	USD
CY2021Q4	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	0.2	USD
CY2021Q1	kern	Installmentamount Installmentamount	2062500	USD
CY2021Q4	us-gaap	Debt Instrument Annual Principal Payment DebtInstrumentAnnualPrincipalPayment	20000000	USD
CY2021Q4	kern	Debt Instrument Interest Rate Original Issue Discount Percentage DebtInstrumentInterestRateOriginalIssueDiscountPercentage	0.10	pure
CY2021Q4	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	3300000	USD
CY2021Q4	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	4050000.00
CY2021Q4	kern	Conversion Price Percentage ConversionPricePercentage	0.80	pure
CY2021	us-gaap	Debt Instrument Increase Decrease For Period Net DebtInstrumentIncreaseDecreaseForPeriodNet	30000.00	USD
CY2021	us-gaap	Other Expenses OtherExpenses	0.7	USD
CY2020Q2	us-gaap	Long Term Debt Description LongTermDebtDescription	the Company issued a promissory note to KeyBank National Association (“KeyBank”) in the principal aggregate amount of $2,204,600 (the “PPP Loan”) pursuant to the Paycheck Protection Program under the CARES Act. The PPP Loan had a two-year term bearing interest at a rate of 1% per annum with principal and interest payments of $92,818 to be paid monthly on the 12th of the month beginning 7 months from the date of the PPP Loan. The PPP Loan provides for prepayment of 20% or less of the unpaid principal balance at any time. If more than 20% is prepaid, then all accrued interest must also be paid.
CY2021Q3	kern	Convertible Notes Bear Interest Rate ConvertibleNotesBearInterestRate	1	pure
CY2021Q3	kern	Convertible Notes Bear Interest Rate ConvertibleNotesBearInterestRate	1	pure
CY2021Q3	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	2234730	USD
CY2021Q4	us-gaap	Long Term Debt And Capital Lease Obligations Repayments Of Principal In Next Twelve Months LongTermDebtAndCapitalLeaseObligationsRepaymentsOfPrincipalInNextTwelveMonths	13200000	USD
CY2021Q4	us-gaap	Long Term Debt And Capital Lease Obligations Maturities Repayments Of Principal In Year Two LongTermDebtAndCapitalLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearTwo	6800000	USD
CY2021Q4	kern	Aggregate Maturities AggregateMaturities	20000000	USD
CY2021Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	2000000	USD
CY2021Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	695000	USD
CY2021Q4	us-gaap	Long Term Debt LongTermDebt	17305000	USD
CY2021Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	13200000	USD
CY2021Q4	kern	Longterm Debt Non Current Maturities LongtermDebtNonCurrentMaturities	4105000	USD
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021	us-gaap	Common Stock Voting Rights CommonStockVotingRights	one
CY2019Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	5813804	shares
CY2019Q4	kern	Warrants Weighted Average Grant Date Fair Value WarrantsWeightedAverageGrantDateFairValue	11.5
CY2019	kern	Warrants Outstanding Weighted Average Remaining Contractual Term WarrantsOutstandingWeightedAverageRemainingContractualTerm	P3Y11M19D
CY2019Q2	kern	Warrants Aggregate Intrinsic Value Outstanding WarrantsAggregateIntrinsicValueOutstanding		USD
	kern	Weighted Average Remaining Life Term Issued WeightedAverageRemainingLifeTermIssued
CY2020Q4	kern	Aggregate Intrinsic Value Issued AggregateIntrinsicValueIssued		USD
CY2020Q4	kern	Aggregate Intrinsic Value Exercised AggregateIntrinsicValueExercised		USD
	kern	Warrants Forfeited In Period Number Of Shares WarrantsForfeitedInPeriodNumberOfShares		shares
	kern	Warrants Forfeited In Period Weighted Average Grant Date Fair Value WarrantsForfeitedInPeriodWeightedAverageGrantDateFairValue
	kern	Weighted Average Rmaining Life Expired WeightedAverageRmainingLifeExpired
CY2020Q4	kern	Aggregate Intrinsic Value Expiredcancelled AggregateIntrinsicValueExpiredcancelled		USD
CY2020Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	5813804	shares
CY2021Q4	kern	Warrants Weighted Average Grant Date Fair Value WarrantsWeightedAverageGrantDateFairValue	11.5
	kern	Warrants Outstanding Weighted Average Remaining Contractual Term WarrantsOutstandingWeightedAverageRemainingContractualTerm	P3Y4M13D
CY2020Q4	kern	Warrants Aggregate Intrinsic Value Outstanding WarrantsAggregateIntrinsicValueOutstanding		USD
CY2021	kern	Warrants Issued In Period Number Of Shares WarrantsIssuedInPeriodNumberOfShares		shares
CY2021	kern	Warrants Issued In Period Weighted Average Grant Date Fair Value WarrantsIssuedInPeriodWeightedAverageGrantDateFairValue
CY2021	kern	Weighted Average Remaining Life Term Issued WeightedAverageRemainingLifeTermIssued
CY2021Q4	kern	Aggregate Intrinsic Value Issued AggregateIntrinsicValueIssued		USD
CY2021	kern	Warrants Exercised In Period Number Of Shares WarrantsExercisedInPeriodNumberOfShares		shares
CY2021	kern	Warrants Exercised In Period Weighted Average Grant Date Fair Value WarrantsExercisedInPeriodWeightedAverageGrantDateFairValue
CY2021	kern	Weighted Average Remaining Life Term Exercised WeightedAverageRemainingLifeTermExercised
CY2021Q4	kern	Aggregate Intrinsic Value Exercised AggregateIntrinsicValueExercised		USD
CY2021	kern	Warrants Forfeited In Period Number Of Shares WarrantsForfeitedInPeriodNumberOfShares		shares
CY2021	kern	Warrants Forfeited In Period Weighted Average Grant Date Fair Value WarrantsForfeitedInPeriodWeightedAverageGrantDateFairValue
CY2021	kern	Weighted Average Rmaining Life Expired WeightedAverageRmainingLifeExpired
CY2021Q4	kern	Aggregate Intrinsic Value Expiredcancelled AggregateIntrinsicValueExpiredcancelled		USD
CY2021Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	5813804	shares
CY2021Q4	kern	Warrants Weighted Average Grant Date Fair Value WarrantsWeightedAverageGrantDateFairValue	11.5
CY2021	kern	Warrants Outstanding Weighted Average Remaining Contractual Term WarrantsOutstandingWeightedAverageRemainingContractualTerm	P2Y11M19D
CY2021Q4	kern	Warrants Aggregate Intrinsic Value Outstanding WarrantsAggregateIntrinsicValueOutstanding		USD
CY2020Q4	kern	Aggregate Intrinsic Value AggregateIntrinsicValue	0	USD
CY2021Q4	kern	Aggregate Intrinsic Value AggregateIntrinsicValue	0	USD
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	6.56
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	429974	shares
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	4.88
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	165374	shares
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	5.08
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	43906	shares
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	6.83
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	827309	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	6.77
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	447642	shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	458270	shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	100520	shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	716161	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2	USD
	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	0.2	USD
	kern	Changes In Fair Value Reported In Statements Of Operations ChangesInFairValueReportedInStatementsOfOperations	961273	USD
	kern	Change In Fair Value Reported In Other Comprehensive Income ChangeInFairValueReportedInOtherComprehensiveIncome	133000	USD
CY2020Q4	us-gaap	Convertible Debt Fair Value Disclosures ConvertibleDebtFairValueDisclosures	13398000	USD
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	19323646	shares
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10559322	shares
CY2020	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	998000	USD
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	6300000	USD
CY2020Q2	us-gaap	Convertible Debt ConvertibleDebt	17	USD
CY2020Q2	kern	Debt Purchase Price DebtPurchasePrice	15	USD
CY2020Q3	us-gaap	Convertible Debt Fair Value Disclosures ConvertibleDebtFairValueDisclosures	14131000	USD
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	1827273	USD
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	15172727	USD
	kern	Changes In Fair Value Reported In Statements Of Operations ChangesInFairValueReportedInStatementsOfOperations	2030904	USD
	kern	Change In Fair Value Reported In Other Comprehensive Income ChangeInFairValueReportedInOtherComprehensiveIncome	70000	USD
	kern	Gainonextinguishmentofdebtreportedonthestatementofoperations Gainonextinguishmentofdebtreportedonthestatementofoperations	186177	USD
CY2021Q4	us-gaap	Convertible Debt Fair Value Disclosures ConvertibleDebtFairValueDisclosures		USD
CY2021Q4	us-gaap	Convertible Debt ConvertibleDebt	20000000	USD
CY2021Q4	kern	Debt Purchase Price DebtPurchasePrice	18000000	USD
CY2021Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	20000000	USD
CY2020Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	15172272	USD
CY2021Q4	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	4.05
CY2020Q4	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	11.5
CY2021Q4	kern	Fair Value Assumptions Value Of Common Stock FairValueAssumptionsValueOfCommonStock	1.75
CY2020Q4	kern	Fair Value Assumptions Value Of Common Stock FairValueAssumptionsValueOfCommonStock	3.24
CY2021	kern	Fair Value Assumption Expected Terms FairValueAssumptionExpectedTerms	P2Y9M18D
CY2020	kern	Fair Value Assumption Expected Terms FairValueAssumptionExpectedTerms	P2Y3M18D
CY2021	kern	Fair Value Assumptions Volatility Rate FairValueAssumptionsVolatilityRate	0.75	pure
CY2020	kern	Fair Value Assumptions Volatility Rate FairValueAssumptionsVolatilityRate	0.77	pure
CY2021	kern	Fair Value Assumptions Market Yield Rate FairValueAssumptionsMarketYieldRate	0.371	pure
CY2021	kern	Fair Value Assumption Risk Free Interest Rate FairValueAssumptionRiskFreeInterestRate	0.01	pure
CY2020	kern	Fair Value Assumption Risk Free Interest Rate FairValueAssumptionRiskFreeInterestRate	0.001	pure
CY2021	us-gaap	Debt Instrument Issuance Date1 DebtInstrumentIssuanceDate1	2021-10-05
CY2020	us-gaap	Debt Instrument Issuance Date1 DebtInstrumentIssuanceDate1	2020-06-09
CY2021	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2024-10-05
CY2020	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2023-06-01
CY2021	kern	Equity Instrument Convertible Conversion Ratio EquityInstrumentConvertibleConversionRatio	0.01	pure
CY2021	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	157593	USD
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	552861	USD
CY2020	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	299629	USD
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	5800	USD
	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	200	USD
CY2021Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	252525	USD
CY2021Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	260100	USD
CY2021Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two And Three Years OperatingLeasesFutureMinimumPaymentsDueInTwoAndThreeYears	110480	USD
CY2021Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	623105	USD
CY2021Q3	kern	Termination Fee TerminationFee	980000	USD
CY2021Q4	kern	Assets Written Off AssetsWrittenOff	1045209	USD
CY2021Q4	us-gaap	Security Deposit SecurityDeposit	41250	USD
CY2021Q4	kern	Termination Fee TerminationFee	402480	USD
CY2021Q4	us-gaap	Share Price SharePrice	3.55
CY2020Q4	kern	Issued And Outstanding Shares Percentage IssuedAndOutstandingSharesPercentage	0.05	pure
CY2020Q2	us-gaap	Bridge Loan BridgeLoan	2200000	USD
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		USD
	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		USD
CY2020	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	30985	USD
CY2020	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit		USD
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	6270	USD
	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit		USD
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	12070	USD
	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	200	USD
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	30985	USD
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	2274295	USD
CY2020	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit		USD
CY2020	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit		USD
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit		USD
CY2020	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit		USD
CY2020	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit		USD
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	2274295	USD
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit		USD
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit		USD
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-6692267	USD
CY2020	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-3560998	USD
CY2020	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-3255706	USD
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-672148	USD
CY2020	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-553871	USD
CY2020	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-862690	USD
CY2021	us-gaap	Income Tax Reconciliation Tax Settlements Foreign IncomeTaxReconciliationTaxSettlementsForeign	-138292	USD
CY2020	us-gaap	Income Tax Reconciliation Tax Settlements Foreign IncomeTaxReconciliationTaxSettlementsForeign	29617	USD
CY2020	us-gaap	Income Tax Reconciliation Tax Settlements Foreign IncomeTaxReconciliationTaxSettlementsForeign	-2645	USD
CY2021	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	2428631	USD
CY2020	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	1263151	USD
CY2020	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	312525	USD
CY2021	kern	Ratechange Ratechange	54295	USD
CY2020	kern	Ratechange Ratechange	60220	USD
CY2020	kern	Ratechange Ratechange		USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Legal Settlements DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements	146604	USD
CY2020Q4	kern	Deferred Tax Assets Revenue Recognition DeferredTaxAssetsRevenueRecognition		USD
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	3361603	USD
CY2020	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	2762081	USD
CY2020	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	3884440	USD
CY2021	kern	Income Tax Reconciliation Provision Return Adjustment IncomeTaxReconciliationProvisionReturnAdjustment	273489	USD
CY2020	kern	Income Tax Reconciliation Provision Return Adjustment IncomeTaxReconciliationProvisionReturnAdjustment		USD
CY2020	kern	Income Tax Reconciliation Provision Return Adjustment IncomeTaxReconciliationProvisionReturnAdjustment	-45134	USD
CY2021	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems		USD
CY2020	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems		USD
CY2020	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems		USD
CY2021	kern	Deferred True Ups DeferredTrueUps	-928743	USD
CY2020	kern	Deferred True Ups DeferredTrueUps		USD
CY2020	kern	Deferred True Ups DeferredTrueUps		USD
CY2021	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	51207	USD
CY2020	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments		USD
CY2020	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	195	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-2262225	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	200	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	30985	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	820410	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	679106	USD
CY2021Q4	kern	Deferred Tax Assets Debt Issuance Costs DeferredTaxAssetsDebtIssuanceCosts	138778	USD
CY2020Q4	kern	Deferred Tax Assets Debt Issuance Costs DeferredTaxAssetsDebtIssuanceCosts	343612	USD
CY2021Q4	kern	Deferred Tax Assets Revenue Recognition DeferredTaxAssetsRevenueRecognition	105735	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Legal Settlements DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements	182896	USD
CY2021Q4	kern	Deferred Tax Assets Fixed Assets DeferredTaxAssetsFixedAssets	242006	USD
CY2020Q4	kern	Deferred Tax Assets Fixed Assets DeferredTaxAssetsFixedAssets	831196	USD
CY2021Q4	us-gaap	Deferred Tax Assets Charitable Contribution Carryforwards DeferredTaxAssetsCharitableContributionCarryforwards	10673908	USD
CY2020Q4	us-gaap	Deferred Tax Assets Charitable Contribution Carryforwards DeferredTaxAssetsCharitableContributionCarryforwards	6337897	USD
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	4904857	USD
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	2586671	USD
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	225340	USD
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	27410	USD
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	17257638	USD
CY2020Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	10988788	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment		USD
CY2020Q2	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment		USD
CY2021Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssets	6051459	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssets	2717717	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	6051459	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	2717717	USD
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	11881470	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	8271071	USD
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	675291	USD
CY2020Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities		USD
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	3600000	USD
CY2021Q4	kern	Purchase Price Value PurchasePriceValue	200000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities Deferred Expense DeferredTaxLiabilitiesDeferredExpense	3400000	USD
	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	5500000	USD
CY2020Q4	kern	Purchase Price Value PurchasePriceValue	2700000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Deferred Expense DeferredTaxLiabilitiesDeferredExpense	2800000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	44500000	USD
CY2021	us-gaap	Other Information Pertaining To Income Taxes OtherInformationPertainingToIncomeTaxes	We have deferred tax assets related to foreign net operating loss carryforward, which begin to expire in 2034, in the amount of $18.5 million.
CY2021Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	30000	USD
CY2020Q2	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	50000	USD
CY2021	us-gaap	Reclassifications Reclassifications	<p style="margin: 0pt; text-align: justify;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Note 16 – <span>Revisions of Previously Issued Financial Statements</span></span></p> <p style="margin: 0pt; text-align: justify;"><br/></p> <p style="text-align: justify; text-indent: 36pt; margin: 0cm; font-size: 10pt; font-family: 'Times New Roman', serif; line-height: 1.2;"><span style="color: #000000; font-family: 'times new roman', times; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: justify; text-indent: 48px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt;">On June 17, 2019, we completed the Mergers with MTech. Prior to the Mergers, MTech was a special purpose acquisition company and had completed an initial public offering in October 2018, which included the issuances of the MTech Private Warrants in a simultaneous private placement transaction. The MTech Private Warrants were exchanged for our Private Warrants as part of the Mergers and our Private Warrants remain outstanding as of December 31, 2021.<span> </span></span><span style="color: #000000; font-family: 'times new roman', times; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: justify; text-indent: 48px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt;">We initially accounted for these outstanding Private Warrants as components of equity rather than as derivative liabilities. In light of the Staff Statement on Accounting and Reporting Considerations for Warrants Issued by Special Purpose Acquisition Companies (“SPACs”) issued by the staff of the SEC on April 12, 2021 (the “SEC Staff Statement”), the Company’s management further evaluated our outstanding warrants under Accounting Standards Codification 815-40, Contracts in Entity’s Own Equity (“ASC 815-40”), which addresses equity versus liability treatment and classification of equity-linked financial instruments, including warrants, and states that a warrant may be classified as a component of equity only if, among other things, the warrant is indexed to the issuer’s common stock.</span></p> <p style="text-align: justify; text-indent: 36pt; margin: 0cm; font-size: 10pt; font-family: 'Times New Roman', serif; line-height: 1.2;"><br/></p> <p style="text-align: justify; text-indent: 36pt; margin: 0cm; font-size: 10pt; font-family: 'Times New Roman', serif; line-height: 1.2;"><span style="font-family: 'times new roman', times; line-height: inherit;"><span style="font-size: 10pt; color: #000000; line-height: inherit;"><span style="color: black; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: justify; text-indent: 48px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-family: 'Times New Roman', 'serif';">Based on management’s evaluation and in consultation with the Audit Committee, we concluded that the Company’s Private Warrants are not indexed to the Company’s common stock in the manner contemplated by ASC Section 815-40.</span><span style="color: #000000; font-family: 'Times New Roman', serif; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: justify; text-indent: 48px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span> </span>As a result, these warrants are precluded from equity classification and should be recorded as derivative liabilities remeasured to fair value at each reporting period. We assessed the materiality of these errors on prior periods’ consolidated financial statements and concluded that the errors were not material to any prior annual or interim periods. However, we have revised the prior period financial information included in these consolidated financial statements to</span><span style="color: #000000; font-family: 'Times New Roman', serif; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: justify; text-indent: 48px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"> reclassify the Private Warrants as derivative liabilities measured at their estimated fair values at the end of each reporting period and recognized changes in the estimated fair value of the derivative instruments from the prior period in the Company’s operating results.</span><span style="color: #000000; font-family: 'Times New Roman', serif; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: justify; text-indent: 48px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"> </span></span></span></p> <p style="text-align: justify; text-indent: 36pt; margin: 0cm; font-size: 10pt; font-family: 'Times New Roman', serif; line-height: 1.2;"><br/></p> <p style="text-align: justify; text-indent: 36pt; margin: 0cm; font-size: 10pt; font-family: 'Times New Roman', serif; line-height: 1.2;"><span style="font-family: 'times new roman', times; line-height: inherit;"><span style="font-size: 10pt; color: #000000; line-height: inherit;"><span style="color: #000000; font-family: 'Times New Roman', serif; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: justify; text-indent: 48px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span style="color: #000000; font-family: 'Times New Roman', serif; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: justify; text-indent: 44.4667px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;">The Company's change in accounting for the Private Warrants from components of equity to derivative liabilities has no impact on the Company's current or previously reported cash position. </span><br/></span></span></span></p> <p style="text-align: justify; text-indent: 36pt; margin: 0cm; font-size: 10pt; font-family: 'Times New Roman', serif; line-height: 1.2;"><br/></p> <p style="text-align: justify; text-indent: 36pt; margin: 0cm; font-size: 10pt; font-family: 'Times New Roman', serif; line-height: 1.2;"><span style="font-family: 'times new roman', times; line-height: inherit;"><span style="font-size: 10pt; color: #000000; line-height: inherit;"><span style="color: #000000; font-family: 'times new roman', times; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: justify; text-indent: 44.4667px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;">The tables below disclose the effects on the consolidated financial statements included in this Annual Report on Form 10-K: </span></span></span></p> <p style="margin: 0pt; text-align: justify; line-height: 1.2;"><br/></p> <div style="border-left: none; border-right: none;"> <div style="border-left: none; border-right: none;"> <div style="border-left: none; border-right: none;"> <div style="border-left: none; border-right: none;"> <div id="t_ft_3L62CHD39C00000000000000000000b"> <table cellpadding="0" style="height: 102px; border-collapse: collapse; font-family: 'times new roman'; font-size: 10pt; width: 100%; margin-left: auto; margin-right: auto;" width="100%"> <tbody> <tr style="height: 17px;"> <td style="vertical-align: bottom; height: 17px; width: 62.9428%;"><br/></td> <td style="vertical-align: bottom; height: 17px; width: 0.980926%;"><br/></td> <td colspan="8" style="vertical-align: bottom; height: 17px; border-bottom: 1px solid #000000; text-align: center; width: 34.97%;"><b><span style="font-size: 10.0pt; font-family: 'Times New Roman','serif'; mso-fareast-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;">Year Ended June 30, 2020</span></b><br/></td> <td style="vertical-align: middle; padding: 0px; height: 17px; width: 1.03542%;"><br/></td> </tr> <tr style="height: 17px;"> <td style="vertical-align: bottom; height: 17px; width: 62.9428%;"><br/></td> <td style="vertical-align: bottom; height: 17px; width: 0.980926%;"><br/></td> <td colspan="2" style="vertical-align: bottom; height: 17px; border-bottom: 1px solid #000000; text-align: center; width: 11%;"><span style="font-weight: bold;"><span>As report</span>ed</span><br/></td> <td style="text-align: left; vertical-align: middle; padding: 0px; height: 17px; width: 0.980926%; border-bottom-width: 1px;"><br/></td> <td colspan="2" style="vertical-align: bottom; height: 17px; text-align: center; border-bottom: 1px solid #000000; width: 11%;"><span style="font-weight: bold;">Adjustment</span><br/></td> <td style="vertical-align: bottom; text-align: right; height: 17px; width: 0.980926%; border-bottom-width: 1px;"><br/></td> <td style="vertical-align: bottom; text-align: left; height: 17px; width: 1.03542%; border-bottom-width: 1px;"><br/></td> <td style="vertical-align: bottom; height: 17px; border-bottom: 1px solid #000000; text-align: center; width: 9.97275%;"><span style="font-weight: bold;">As revised</span></td> <td style="vertical-align: middle; padding: 0px; height: 17px; width: 1.03542%;"><br/></td> </tr> <tr style="height: 17px; background-color: #cceeff;"> <td style="vertical-align: bottom; width: 62.9428%; height: 17px; background-color: #cceeff;"><b style="color: #000000; font-family: 'times new roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Consolidated <span style="vertical-align: bottom; height: 17px; padding: 0px 2px 0px 0px; width: 65.6593%; font-style: normal; text-decoration: none; color: black;">Statements</span> of Operations</b></td> <td style="vertical-align: bottom; width: 0.980926%; height: 17px; background-color: #cceeff;"><br/></td> <td style="vertical-align: bottom; text-align: left; width: 1%; height: 17px; background-color: #cceeff; border-bottom-width: 1px;"><br/></td> <td style="vertical-align: bottom; text-align: right; width: 10%; height: 17px; background-color: #cceeff; border-bottom-width: 1px;"><br/></td> <td style="text-align: left; vertical-align: middle; padding: 0px; width: 0.980926%; height: 17px; background-color: #cceeff; border-bottom-width: 1px;"><br/></td> <td style="vertical-align: bottom; text-align: left; width: 1%; height: 17px; background-color: #cceeff; border-bottom-width: 1px;"><br/></td> <td style="vertical-align: bottom; text-align: right; width: 10%; height: 17px; background-color: #cceeff; border-bottom-width: 1px;"><br/></td> <td style="vertical-align: bottom; text-align: left; width: 0.980926%; height: 17px; background-color: #cceeff; border-bottom-width: 1px;"><br/></td> <td style="vertical-align: bottom; text-align: left; width: 1.03542%; height: 17px; background-color: #cceeff; border-bottom-width: 1px;"><br/></td> <td style="vertical-align: bottom; text-align: right; width: 9.97275%; height: 17px; background-color: #cceeff; border-bottom-width: 1px;"><br/></td> <td style="vertical-align: middle; padding: 0px; width: 1.03542%; height: 17px; background-color: #cceeff;"><br/></td> </tr> <tr style="height: 17px;"> <td style="vertical-align: bottom; height: 17px; width: 62.9428%;"><span style="color: #000000; font-family: 'times new roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;"><span style="color: #000000; font-family: 'times new roman', times; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;">Change in fair value of derivative liability</span></span><br/></td> <td style="vertical-align: bottom; height: 17px; width: 0.980926%;"><br/></td> <td style="vertical-align: bottom; text-align: left; height: 17px; width: 1%; border-bottom-width: 1px;"><br/></td> <td style="vertical-align: bottom; text-align: right; height: 17px; width: 10%; border-bottom-width: 1px;">—</td> <td style="text-align: left; vertical-align: middle; padding: 0px; height: 17px; width: 0.980926%; border-bottom-width: 1px;"><br/></td> <td style="vertical-align: bottom; text-align: left; height: 17px; width: 1%; border-bottom-width: 1px;"><br/></td> <td style="vertical-align: bottom; text-align: right; height: 17px; width: 10%; border-bottom-width: 1px;">1,962,034</td> <td style="vertical-align: bottom; height: 17px; text-align: left; width: 0.980926%; border-bottom-width: 1px;"/> <td style="vertical-align: bottom; text-align: left; height: 17px; width: 1.03542%; border-bottom-width: 1px;"><br/></td> <td style="vertical-align: bottom; text-align: right; height: 17px; width: 9.97275%; border-bottom-width: 1px;">1,962,034</td> <td style="vertical-align: middle; padding: 0px; height: 17px; width: 1.03542%;"><br/></td> </tr> <tr style="height: 17px; background-color: #cceeff;"> <td style="vertical-align: bottom; height: 17px; width: 62.9428%; background-color: #cceeff;"><span style="color: #000000; font-family: 'times new roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;"><span style="color: #000000; font-family: 'times new roman', times; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;">Net loss<span> </span></span><span style="color: #000000; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-family: 'Times New Roman', serif;">attributable to Akerna shareholders</span></span></td> <td style="vertical-align: bottom; height: 17px; width: 0.980926%; background-color: #cceeff;"><br/></td> <td style="vertical-align: bottom; text-align: left; height: 17px; width: 1%; background-color: #cceeff;"><br/></td> <td style="vertical-align: bottom; text-align: right; height: 17px; width: 10%; background-color: #cceeff;">(15,534,345)</td> <td style="text-align: left; vertical-align: middle; padding: 0px; height: 17px; width: 0.980926%; background-color: #cceeff;"><br/></td> <td style="vertical-align: bottom; text-align: left; height: 17px; width: 1%; background-color: #cceeff;"><br/></td> <td style="vertical-align: bottom; text-align: right; height: 17px; width: 10%; background-color: #cceeff;">1,962,034</td> <td style="vertical-align: bottom; text-align: right; height: 17px; width: 0.980926%; background-color: #cceeff;"><br/></td> <td style="vertical-align: bottom; text-align: left; height: 17px; width: 1.03542%; background-color: #cceeff;"><br/></td> <td style="vertical-align: bottom; text-align: right; height: 17px; width: 9.97275%; background-color: #cceeff;">(13,572,311)</td> <td style="vertical-align: middle; padding: 0px; height: 17px; width: 1.03542%; background-color: #cceeff;"><br/></td> </tr> <tr style="height: 17px;"> <td style="vertical-align: bottom; height: 17px; width: 62.9428%;"><span style="color: #000000; font-family: 'times new roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;"><span style="color: #000000; font-family: 'times new roman', times; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;">Net loss per share</span></span></td> <td style="vertical-align: bottom; height: 17px; width: 0.980926%;"><br/></td> <td style="vertical-align: bottom; text-align: left; height: 17px; width: 1%;"><br/></td> <td style="vertical-align: bottom; text-align: right; height: 17px; width: 10%;">(1.31)</td> <td style="text-align: left; vertical-align: middle; padding: 0px; height: 17px; width: 0.980926%;"><br/></td> <td style="vertical-align: bottom; text-align: left; height: 17px; width: 1%;"><br/></td> <td style="vertical-align: bottom; text-align: right; height: 17px; width: 10%;">—</td> <td style="vertical-align: bottom; height: 17px; text-align: left; width: 0.980926%;"/> <td style="vertical-align: bottom; text-align: left; height: 17px; width: 1.03542%;"><br/></td> <td style="vertical-align: bottom; text-align: right; height: 17px; width: 9.97275%;">(1.14)</td> <td style="vertical-align: middle; padding: 0px; height: 17px; width: 1.03542%;"><br/></td> </tr> </tbody> </table> </div> <div id="t_ft_GREZQMHN9C00000000000000000000b"> <table cellpadding="0" style="height: 116px; border-collapse: collapse; font-family: 'times new roman'; font-size: 10pt; width: 100%; margin-left: 0.1px;" width="100%"> <tbody> <tr style="height: 17px;"> <td style="vertical-align: bottom; height: 17px; margin: 0pt; padding-right: 8px;"> <p><br/></p> </td> <td style="vertical-align: bottom; height: 17px; margin: 0pt; padding-right: 8px;"><br/></td> <td colspan="8" style="vertical-align: bottom; text-align: center; height: 17px;"> <p style="text-align: center;"><br/></p> <p style="border-bottom: 1px solid #000000; text-align: center;"><span style="font-weight: bold; text-align: center;"><b style="text-align: center;"><span style="font-size: 10.0pt; font-family: 'Times New Roman','serif'; mso-fareast-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA; text-align: center;">Six Months Ended December 31, 2020</span></b></span></p> </td> <td style="vertical-align: bottom; height: 17px; white-space: nowrap;"><br/></td> </tr> <tr style="height: 17px;"> <td style="vertical-align: bottom; height: 17px; margin: 0pt; padding-right: 8px;"><br/></td> <td style="vertical-align: bottom; height: 17px; margin: 0pt; padding-right: 8px;"/> <td colspan="2" style="vertical-align: bottom; height: 17px; text-align: center; border-bottom: 1px solid #000000;"><span style="font-weight: bold; text-align: center;">As reported</span></td> <td style="height: 17px; vertical-align: bottom; text-align: center; white-space: nowrap;" valign="middle"/> <td colspan="2" style="vertical-align: bottom; height: 17px; text-align: center; white-space: nowrap; border-bottom: 1px solid #000000;"><span style="font-weight: bold; margin: 0pt; text-align: center;">Adjustment</span></td> <td style="vertical-align: bottom; height: 17px; text-align: center; white-space: nowrap;"/> <td colspan="2" style="vertical-align: bottom; height: 17px; text-align: center; white-space: nowrap; border-bottom: 1px solid #000000;"><span style="font-weight: bold; margin: 0pt; text-align: center;">As revised</span></td> <td style="height: 17px; vertical-align: bottom; white-space: nowrap;" valign="middle"><br/></td> </tr> <tr style="height: 17px; background-color: #cceeff;"> <td style="text-indent: 0px; margin-left: 0.1px; vertical-align: bottom; height: 17px; width: 63%; background-color: #cceeff;"><span style="font-weight: bold;">Condensed Consolidated Statements of Operations</span></td> <td style="height: 17px; margin: 0pt; padding-right: 8px; vertical-align: bottom; width: 1%; background-color: #cceeff;"><br/></td> <td style="text-align: left; height: 17px; margin: 0pt; padding-right: 8px; vertical-align: bottom; width: 1%; background-color: #cceeff;"><br/></td> <td style="vertical-align: bottom; text-align: right; height: 17px; white-space: nowrap; width: 10%; background-color: #cceeff;"><br/></td> <td style="text-align: left; vertical-align: bottom; height: 17px; white-space: nowrap; width: 1%; background-color: #cceeff;"><br/></td> <td style="vertical-align: bottom; text-align: left; height: 17px; white-space: nowrap; width: 1%; background-color: #cceeff;"><br/></td> <td style="vertical-align: bottom; text-align: right; height: 17px; white-space: nowrap; width: 10%; background-color: #cceeff;"><br/></td> <td style="vertical-align: bottom; text-align: left; height: 17px; white-space: nowrap; width: 1%; background-color: #cceeff;"><br/></td> <td style="vertical-align: bottom; text-align: left; height: 17px; white-space: nowrap; width: 1%; background-color: #cceeff;"><br/></td> <td style="vertical-align: bottom; text-align: right; height: 17px; white-space: nowrap; width: 10%; background-color: #cceeff;"><br/></td> <td style="vertical-align: bottom; height: 17px; white-space: nowrap; width: 1%; background-color: #cceeff;"><br/></td> </tr> <tr style="height: 14px;"> <td style="height: 14px; text-indent: 0px; margin-left: 0.1px; vertical-align: bottom;"><span style="vertical-align: bottom; height: 17px; padding: 0px 2px 0px 0px; width: 65.6593%;"><span style="color: #000000; font-family: 'times new roman', times; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;">Change in fair value of derivative liability</span></span></td> <td style="vertical-align: bottom; height: 14px; margin: 0pt; padding-right: 8px;"> <p style="margin: 0pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span></p> </td> <td style="vertical-align: bottom; height: 14px; text-align: left; margin: 0pt; padding-right: 8px;"> <p style="margin: 0pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span></p> </td> <td align="right" style="height: 14px; white-space: nowrap; margin: 0pt; vertical-align: bottom;"><span style="margin: 0pt;"><span style="border-left: none; border-right: none;">—</span></span></td> <td style="height: 14px; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="middle"/> <td style="vertical-align: bottom; height: 14px; text-align: left; white-space: nowrap;"><br/></td> <td align="right" style="height: 14px; white-space: nowrap; margin: 0pt; vertical-align: bottom;"><span style="margin: 0pt;">746,852</span></td> <td align="left" style="height: 14px; white-space: nowrap; padding-right: 8px; margin: 0pt; vertical-align: bottom;"/> <td style="vertical-align: bottom; height: 14px; text-align: left; white-space: nowrap;"><br/></td> <td align="right" style="height: 14px; white-space: nowrap; margin: 0pt; vertical-align: bottom;"><span style="margin: 0pt;">746,852</span></td> <td style="height: 14px; vertical-align: bottom; white-space: nowrap;" valign="middle"/> </tr> <tr style="height: 17px; background-color: #cceeff;"> <td style="vertical-align: bottom; height: 17px; text-indent: 0px; background-color: #cceeff;"><span style="color: #000000; font-family: 'times new roman', times; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;">Net loss<span> </span></span><span style="color: #000000; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-family: 'Times New Roman', serif;">attributable to Akerna shareholders</span><br/></td> <td style="vertical-align: bottom; height: 17px; margin: 0pt; padding-right: 8px; background-color: #cceeff;"> <p style="margin: 0pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span></p> </td> <td style="vertical-align: bottom; height: 17px; text-align: left; margin: 0pt; padding-right: 8px; background-color: #cceeff;"><br/></td> <td align="right" style="height: 17px; white-space: nowrap; margin: 0pt; vertical-align: bottom; background-color: #cceeff;"><span style="margin: 0pt;">(<span style="border-left: none; border-right: none;">16,957,334</span>)</span></td> <td style="height: 17px; text-align: left; vertical-align: bottom; white-space: nowrap; background-color: #cceeff;" valign="middle"><br/></td> <td style="vertical-align: bottom; height: 17px; text-align: left; white-space: nowrap; background-color: #cceeff;"><br/></td> <td align="right" style="height: 17px; white-space: nowrap; margin: 0pt; vertical-align: bottom; background-color: #cceeff;"><span style="margin: 0pt;"><span style="border-right: none; border-left: none;">746,852</span></span></td> <td style="vertical-align: bottom; height: 17px; text-align: left; white-space: nowrap; background-color: #cceeff;"><br/></td> <td style="vertical-align: bottom; height: 17px; text-align: left; white-space: nowrap; background-color: #cceeff;"><br/></td> <td align="right" style="height: 17px; white-space: nowrap; margin: 0pt; vertical-align: bottom; background-color: #cceeff;"><span style="margin: 0pt;">(<span style="margin: 0pt;">16,210,482</span>)</span></td> <td style="height: 17px; vertical-align: bottom; white-space: nowrap; background-color: #cceeff;" valign="middle"><br/></td> </tr> <tr style="height: 17px;"> <td style="vertical-align: bottom; height: 17px;"><span style="color: #000000; font-family: 'times new roman', times; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;">Net loss per share</span><br/></td> <td style="vertical-align: bottom; height: 17px; margin: 0pt; padding-right: 8px;"><br/></td> <td style="vertical-align: bottom; height: 17px; text-align: left; margin: 0pt; padding-right: 8px;"><br/></td> <td align="right" style="height: 17px; white-space: nowrap; margin: 0pt; vertical-align: bottom;"><span style="margin: 0pt;">(1.01)</span></td> <td style="height: 17px; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="middle"/> <td style="vertical-align: bottom; height: 17px; text-align: left; white-space: nowrap;"><br/></td> <td align="right" style="height: 17px; white-space: nowrap; margin: 0pt; vertical-align: bottom;"><span style="margin: 0pt;">—</span></td> <td align="left" style="height: 17px; white-space: nowrap; padding-right: 8px; margin: 0pt; vertical-align: bottom;"/> <td style="vertical-align: bottom; height: 17px; text-align: left; white-space: nowrap;"><br/></td> <td align="right" style="height: 17px; white-space: nowrap; margin: 0pt; vertical-align: bottom;"><span style="margin: 0pt;">(1.01)</span></td> <td style="height: 17px; vertical-align: bottom; white-space: nowrap;" valign="middle"/> </tr> </tbody> </table> </div> <p><br/></p> </div> </div> </div> <div style="color: #000000; font-family: 'times new roman', times; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: #ffffff; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; border-left: none; border-right: none;"> <div id="t_ft_K81L1T5K9S00000000000000000000b"> <table cellpadding="0" style="height: 109px; border-collapse: collapse; font-family: 'times new roman'; font-size: 10pt; width: 100%; margin-left: auto; margin-right: auto;" width="100%"> <tbody> <tr style="height: 17px;"> <td style="vertical-align: bottom; height: 17px;"><br/></td> <td style="vertical-align: bottom; height: 17px;"><br/></td> <td colspan="8" style="vertical-align: bottom; text-align: center; height: 17px;"> <p style="margin: 0px; border-bottom: 1px solid #000000;"><span style="font-weight: bold;"><b><span style="font-size: 10pt; font-family: 'Times New Roman', 'serif';">As of December 31, 2020</span></b></span></p> </td> <td style="vertical-align: middle; padding: 0px; height: 17px;"><br/></td> </tr> <tr style="height: 17px;"> <td style="vertical-align: bottom; height: 17px;"><br/></td> <td style="vertical-align: bottom; height: 17px;"/> <td colspan="2" style="vertical-align: bottom; height: 17px; text-align: center; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: #000000;"><span style="font-weight: bold;">As reported</span></td> <td style="height: 17px; vertical-align: middle; padding: 0px; text-align: center;" valign="middle"/> <td colspan="2" style="vertical-align: bottom; height: 17px; text-align: center; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: #000000;"><span style="font-weight: bold;">Adjustment</span></td> <td style="vertical-align: bottom; height: 17px; text-align: center;"/> <td colspan="2" style="vertical-align: bottom; height: 17px; text-align: center; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: #000000;"><span style="font-weight: bold;">As revised</span></td> <td style="height: 17px; vertical-align: middle; padding: 0px;" valign="middle"><br/></td> </tr> <tr style="height: 17px; background-color: #cceeff;"> <td style="padding-top: 0px; padding-right: 0px; padding-bottom: 0px; text-indent: 0px; margin-left: 0.1px; vertical-align: bottom; height: 17px; width: 63%; background-color: #cceeff;"><span style="font-weight: bold;"><b style="color: #000000; font-family: 'times new roman', times; font-size: 12px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: #cceeff; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"><span style="color: black;">Consolidated Balance Sheet</span></b><br/></span></td> <td style="vertical-align: bottom; height: 17px; width: 1%; background-color: #cceeff;"><br/></td> <td style="vertical-align: bottom; text-align: left; height: 17px; width: 1%; background-color: #cceeff; border-bottom-width: 1px;"><br/></td> <td style="vertical-align: bottom; text-align: right; height: 17px; width: 10%; background-color: #cceeff; border-bottom-width: 1px;"><br/></td> <td style="text-align: left; vertical-align: middle; padding: 0px; height: 17px; width: 1%; background-color: #cceeff; border-bottom-width: 1px;"><br/></td> <td style="vertical-align: bottom; text-align: left; height: 17px; width: 1%; background-color: #cceeff; border-bottom-width: 1px;"><br/></td> <td style="vertical-align: bottom; text-align: right; height: 17px; width: 10%; background-color: #cceeff; border-bottom-width: 1px;"><br/></td> <td style="vertical-align: bottom; text-align: left; height: 17px; width: 1%; background-color: #cceeff; border-bottom-width: 1px;"><br/></td> <td style="vertical-align: bottom; text-align: left; height: 17px; width: 1%; background-color: #cceeff; border-bottom-width: 1px;"><br/></td> <td style="vertical-align: bottom; text-align: right; height: 17px; width: 10%; background-color: #cceeff; border-bottom-width: 1px;"><br/></td> <td style="vertical-align: middle; padding: 0px; height: 17px; width: 1%; background-color: #cceeff;"><br/></td> </tr> <tr style="height: 14px;"> <td style="height: 14px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; text-indent: 0px; margin-left: 0.1px; vertical-align: bottom;"><span style="vertical-align: bottom; height: 17px; padding: 0px 2px 0px 0px; width: 65.6593%;"><span style="color: #000000; font-family: 'times new roman', times; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;">Derivative liability</span></span></td> <td style="vertical-align: bottom; height: 14px;"> <p style="margin: 0pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span></p> </td> <td style="vertical-align: bottom; height: 14px; text-align: left;"> <p style="margin: 0pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span></p> </td> <td style="vertical-align: bottom; height: 14px; text-align: right;">—</td> <td style="height: 14px; text-align: left; vertical-align: middle; padding: 0px;" valign="middle"/> <td style="vertical-align: bottom; height: 14px; text-align: left;"><br/></td> <td style="vertical-align: bottom; height: 14px; text-align: right;">(311,376)</td> <td style="vertical-align: bottom; height: 14px; text-align: left;"/> <td style="vertical-align: bottom; height: 14px; text-align: left;"><br/></td> <td style="vertical-align: bottom; height: 14px; text-align: right;">(311,376)<br/></td> <td style="height: 14px; padding: 0px; vertical-align: middle;" valign="middle"/> </tr> <tr style="background-color: #cceeff; height: 17px;"> <td style="padding-top: 0px; padding-right: 0px; padding-bottom: 0px; text-indent: 0px; margin-left: 0.1px; vertical-align: bottom; background-color: #cceeff; height: 17px;"><span style="color: #000000; font-family: 'times new roman', times; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;">Total liabilities</span></td> <td style="vertical-align: bottom; background-color: #cceeff; height: 17px;"><br/></td> <td style="vertical-align: bottom; text-align: left; background-color: #cceeff; height: 17px;"><br/></td> <td style="vertical-align: bottom; text-align: right; background-color: #cceeff; height: 17px;">(19,635,076)</td> <td style="text-align: left; vertical-align: middle; padding: 0px; background-color: #cceeff; height: 17px;"><br/></td> <td style="vertical-align: bottom; text-align: left; background-color: #cceeff; height: 17px;"><br/></td> <td style="vertical-align: bottom; text-align: right; background-color: #cceeff; height: 17px;">(311,376)</td> <td style="vertical-align: bottom; text-align: left; background-color: #cceeff; height: 17px;"><br/></td> <td style="vertical-align: bottom; text-align: left; background-color: #cceeff; height: 17px;"><br/></td> <td style="vertical-align: bottom; text-align: right; background-color: #cceeff; height: 17px;">(19,946,452)</td> <td style="padding: 0px; vertical-align: middle; background-color: #cceeff; height: 17px;"><br/></td> </tr> <tr style="height: 17px;"> <td style="vertical-align: bottom; height: 17px; padding: 0px 2px 0px 0px;"><span style="color: #000000; font-family: 'times new roman', times; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;">Additional paid-in capital</span><br/></td> <td style="vertical-align: bottom; height: 17px;"><br/></td> <td style="vertical-align: bottom; height: 17px; text-align: left;"><br/></td> <td style="vertical-align: bottom; text-align: right; height: 17px;"><span style="color: #000000; font-family: 'Times New Roman', serif; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: right; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;">95,090,833</span></td> <td style="height: 17px; text-align: left; vertical-align: middle; padding: 0px;" valign="middle"/> <td style="vertical-align: bottom; height: 17px; text-align: left;"><br/></td> <td style="vertical-align: bottom; text-align: right; height: 17px;">(1,004,450)</td> <td style="vertical-align: bottom; height: 17px; text-align: left;"/> <td style="vertical-align: bottom; height: 17px; text-align: left;"><br/></td> <td style="vertical-align: bottom; text-align: right; height: 17px;"><span style="color: #000000; font-family: 'Times New Roman', serif; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: right; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;">94,086,433</span></td> <td style="height: 17px; vertical-align: middle; padding: 0px;" valign="middle"/> </tr> <tr style="height: 10px; background-color: #cceeff;"> <td style="vertical-align: bottom; height: 10px; padding: 0px 2px 0px 0px; background-color: #cceeff;"><span style="color: #000000; font-family: 'times new roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;"><span style="color: #000000; font-family: 'times new roman', times; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;">Accumulated deficit</span></span></td> <td style="vertical-align: bottom; height: 10px; background-color: #cceeff;"> <p style="margin: 0pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span></p> </td> <td style="vertical-align: bottom; height: 10px; text-align: left; background-color: #cceeff;"><br/></td> <td style="vertical-align: bottom; height: 10px; text-align: right; background-color: #cceeff;"><span style="color: #000000; font-family: 'times new roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: right; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;">(57,872,599)</span></td> <td style="height: 10px; text-align: left; vertical-align: middle; padding: 0px; background-color: #cceeff;" valign="middle"/> <td style="vertical-align: bottom; height: 10px; text-align: left; background-color: #cceeff;"><br/></td> <td style="vertical-align: bottom; height: 10px; text-align: right; background-color: #cceeff;"><span style="color: #000000; font-family: 'times new roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: right; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;">693,074</span></td> <td style="vertical-align: bottom; height: 10px; text-align: left; background-color: #cceeff;"/> <td style="vertical-align: bottom; height: 10px; text-align: left; background-color: #cceeff;"><br/></td> <td style="vertical-align: bottom; height: 10px; text-align: right; background-color: #cceeff;">(57,179,525)</td> <td style="height: 10px; vertical-align: middle; padding: 0px; background-color: #cceeff;" valign="middle"/> </tr> </tbody> </table> </div> </div> </div>

Files In Submission

Name	View Source	Status
0001213900-22-016675-index-headers.html	Edgar Link	pending
0001213900-22-016675-index.html	Edgar Link	pending
0001213900-22-016675.txt	Edgar Link	pending
0001213900-22-016675-xbrl.zip	Edgar Link	pending
ex211_2.htm	Edgar Link	pending
ex231_3.htm	Edgar Link	pending
ex311_4.htm	Edgar Link	pending
ex312_5.htm	Edgar Link	pending
ex321_6.htm	Edgar Link	pending
ex34_1.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
kern-20211231.htm	Edgar Link	pending
kern-20211231.xsd	Edgar Link	pending
kern-20211231_cal.xml	Edgar Link	unprocessable
kern-20211231_def.xml	Edgar Link	unprocessable
kern-20211231_htm.xml	Edgar Link	completed
kern-20211231_lab.xml	Edgar Link	unprocessable
kern-20211231_pre.xml	Edgar Link	unprocessable
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$GRYP
Gryphon Digital Mining, Inc. Stock $gryp

2022 Q1 Form 10-K Financial Statement

#000121390022016675 Filed on March 31, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GRYP Gryphon Digital Mining, Inc. Stock $gryp

2022 Q1 Form 10-K Financial Statement

#000121390022016675 Filed on March 31, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GRYP
Gryphon Digital Mining, Inc. Stock $gryp